1
|
Rakotoarisoa L, Weiss L, Lefebvre F, Porzio M, Renaud-Picard B, Ravoninjatovo B, Abely M, Danner-Boucher I, Dubois S, Troussier F, Prevotat A, Rault G, Kessler R, Kessler L. Early glucose abnormalities revealed by continuous glucose monitoring associate with lung function decline in cystic fibrosis: A five-year prospective study. J Diabetes Complications 2024; 38:108703. [PMID: 38430625 DOI: 10.1016/j.jdiacomp.2024.108703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/03/2023] [Revised: 01/22/2024] [Accepted: 02/13/2024] [Indexed: 03/05/2024]
Abstract
BACKGROUND Cystic fibrosis related diabetes (CFRD) is commonly associated with declining lung function and nutritional status. We aimed to evaluate the pulmonary impact of early glucose abnormalities by using 2-h standard oral glucose tolerance testing (OGTT) and continuous glucose monitoring (CGM) in people with cystic fibrosis (PwCF). METHODS PwCF aged ≥10 years old without known CFRD were included in a five-year prospective multicentre study. Annual evaluation of nutritional status, lung function, OGTT and CGM was set up. Associations between annual rate changes (Δ) in lung function, ΔFEV1 (forced expiratory volume in 1 s) percentage predicted (pp) and ΔFVC (forced vital capacity) pp., and annual rate changes in OGTT or CGM variables were estimated with a mixed model with a random effect for subject. RESULTS From 2009 to 2016, 112 PwCF (age: 21 ± 11 years, BMI (body mass index) z-score: -0.55 ± 1.09, FEV1pp: 77 ± 24 %, 2-h OGTT glucose: 122 ± 44 mg/dL, AUC (area under curve) >140 mg/dL: 1 mg/dL/day (0.2, 3.0) were included. A total of 428 OGTTs and 480 CGMs were collected. The participants presented annual decline of FVCpp and FEV1pp at -1.0 % per year (-1.6, -0.4), p < 0.001 and - 1.9 % per year (-2.5, -1.3), p < 0.001 respectively without change in BMI z-score during the study. Variation of two-hour OGTT glucose was not associated with declining lung function, as measured by ΔFEV1pp (p = 0.94) and ΔFVCpp (p = 0.90). Among CGM variables, only increase in AUC >140 mg/dL between two annual visits was associated with a decrease in ΔFVCpp (p < 0.05) and ΔFEV1pp (p < 0.05). CONCLUSIONS This prospective study supports the fact that early glucose abnormalities revealed by CGM predict pulmonary function decline in PwCF, while 2-h standard OGTT glucose is not associated with pulmonary impairment.
Collapse
Affiliation(s)
- Luc Rakotoarisoa
- Department of Endocrinology, Diabetes and Nutrition, Strasbourg University Hospital, France; Adult Cystic Fibrosis Centre, Strasbourg University Hospital, France; UMR Inserm 1260, Regenerative Nanomedicine, University of Strasbourg, France
| | - Laurence Weiss
- Pediatric Cystic Fibrosis Centre, Strasbourg University Hospital, France
| | - François Lefebvre
- Group of Methodology in Clinical Research (GMRC), Strasbourg University Hospital, France
| | - Michele Porzio
- Adult Cystic Fibrosis Centre, Strasbourg University Hospital, France; Department of Pneumology, Strasbourg University Hospital, France
| | - Benjamin Renaud-Picard
- Adult Cystic Fibrosis Centre, Strasbourg University Hospital, France; UMR Inserm 1260, Regenerative Nanomedicine, University of Strasbourg, France; Department of Pneumology, Strasbourg University Hospital, France
| | | | - Michel Abely
- Cystic Fibrosis Centre, Reims University Hospital Centre, France
| | | | | | | | - Anne Prevotat
- Cystic Fibrosis Centre, Lille University Hospital, France
| | - Gilles Rault
- Cystic Fibrosis Centre of Perharidy, Roscoff, France
| | - Romain Kessler
- Adult Cystic Fibrosis Centre, Strasbourg University Hospital, France; UMR Inserm 1260, Regenerative Nanomedicine, University of Strasbourg, France; Department of Pneumology, Strasbourg University Hospital, France
| | - Laurence Kessler
- Department of Endocrinology, Diabetes and Nutrition, Strasbourg University Hospital, France; Adult Cystic Fibrosis Centre, Strasbourg University Hospital, France; UMR Inserm 1260, Regenerative Nanomedicine, University of Strasbourg, France.
| |
Collapse
|
2
|
Reznik Y, Carvalho M, Fendri S, Prevost G, Chaillous L, Riveline JP, Hanaire H, Dubois S, Houéto P, Pasche H, Mianowska B, Renard E. Should people with type 2 diabetes treated by multiple daily insulin injections with home health care support be switched to hybrid closed-loop? The CLOSE AP+ randomized controlled trial. Diabetes Obes Metab 2024; 26:622-630. [PMID: 37921083 DOI: 10.1111/dom.15351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/19/2023] [Revised: 10/15/2023] [Accepted: 10/15/2023] [Indexed: 11/04/2023]
Abstract
AIM The study aim was to evaluate the feasibility, safety and efficacy of automated insulin delivery (AID) assisted by home health care (HHC) services in people with type 2 diabetes unable to manage multiple daily insulin injections (MDI) at home on their own. PATIENTS AND METHODS This was an open label, multicentre, randomized, parallel group trial. In total, 30 adults with type 2 diabetes using MDI and requiring nursing support were randomly allocated to AID or kept their usual therapy over a 12-week period. Both treatments were managed with the support of HHC services. The primary outcome was the percentage time in the target glucose range of 70-180 mg/dl (TIR). Secondary outcomes included other continuous glucose monitoring metrics, glycated haemoglobin (HbA1c) levels, daily insulin doses, body weight, and of quality of life scores, fear of hypoglycaemia and satisfaction questionnaires. RESULTS Age (69.7 vs. 69.3 years) and HbA1c (9.25 vs. 9.0) did not differ in MDI and AID at baseline. Compared with MDI, AID resulted in a significant increase in TIR by 27.4% [95% CI (15.0-39.8); p < .001], a decrease in time above range by 27.7% and an unchanged time below range of <1%. A between-group difference in HbA1c was 1.3% favouring AID. Neither severe hypoglycaemia nor ketoacidosis occurred in either group. Patient and caregiver satisfaction with AID was high. CONCLUSIONS AID combined with tailored HHC services significantly improved glycaemic control with no safety issues in people with type 2 diabetes previously under an MDI regimen with HHC. AID should be considered a safe option in these people when lacking acceptable glucose control.
Collapse
Affiliation(s)
- Yves Reznik
- Endocrinology and Diabetes Department, CHU Côte de Nacre, Caen Cedex, France and Unicaen, Caen Cedex, France
| | - Martin Carvalho
- Diabetology Department, Vert Coteau Clinic, Marseille, France
| | - Salha Fendri
- Diabetology Department, Amiens University Hospital, Amiens, France
| | - Gaetan Prevost
- Normandie Univ, UNIROUEN, Inserm U1239, CHU Rouen, Department of Endocrinology, Diabetes and metabolic diseases and Inserm CIC-CRB 140, Rouen, France
| | - Lucy Chaillous
- Diabetology Department, Nantes University Hospital, Nantes, France
| | - Jean Pierre Riveline
- Centre Universitaire du diabète et de ses complications, APHP, Hôpital Lariboisière, Paris, Île-de-France, France and Institut Necker Enfants Malades, INSERM U1151, CNRS UMR 8253, IMMEDIAB Laboratory, Paris, France
| | - Hélène Hanaire
- Diabetology Department, Rangueil, Toulouse University Hospital, Toulouse, France
| | - Séverine Dubois
- Diabetology Department, Angers University Hospital, Angers, France
| | | | | | - Beata Mianowska
- Department of Pediatrics, Diabetology, Endocrinology and Nephrology, Medical University of Lodz, Lodz, Poland
| | - Eric Renard
- Department of Endocrinology and Diabetes, Montpellier University Hospital, Montpellier, France and Institute of Functional Genomics, University of Montpellier, CNRS, INSERM, Montpellier, France
| |
Collapse
|
3
|
Blandin A, Amosse J, Froger J, Hilairet G, Durcin M, Fizanne L, Ghesquière V, Prieur X, Chaigneau J, Vergori L, Dray C, Pradère JP, Blandin S, Dupont J, Ducluzeau PH, Dubois S, Boursier J, Cariou B, Le Lay S. Extracellular vesicles are carriers of adiponectin with insulin-sensitizing and anti-inflammatory properties. Cell Rep 2023; 42:112866. [PMID: 37605533 DOI: 10.1016/j.celrep.2023.112866] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2022] [Revised: 05/06/2023] [Accepted: 07/11/2023] [Indexed: 08/23/2023] Open
Abstract
Recent evidence supporting that adipose tissue (AT)-derived extracellular vesicles (EVs) carry an important part of the AT secretome led us to characterize the EV-adipokine profile. In addition to evidencing a high AT-derived EV secretion ability that is further increased by obesity, we identify enrichment of oligomeric forms of adiponectin in small EVs (sEVs). This adipokine is mainly distributed at the EV external surface as a result of nonspecific adsorption of soluble adiponectin. EVs also constitute stable conveyors of adiponectin in the blood circulation. Adiponectin-enriched sEVs display in vitro insulin-sensitizing effects by binding to regular adiponectin receptors. Adoptive transfer of adiponectin-enriched sEVs in high-fat-diet-fed mice prevents animals from gaining weight and ameliorated insulin resistance and tissue inflammation, with major effects observed in the AT and liver. Our results therefore provide information regarding adiponectin-related metabolic responses by highlighting EVs as delivery platforms of metabolically active forms of adiponectin molecules.
Collapse
Affiliation(s)
- Alexia Blandin
- L'Institut du Thorax, CNRS, INSERM, Nantes Université, 44000 Nantes, France; Université Angers, SFR ICAT, 49000 Angers, France; L'institut du Thorax, CNRS, INSERM, CHU Nantes, Nantes Université, 44000 Nantes, France
| | - Jérémy Amosse
- Université Angers, SFR ICAT, 49000 Angers, France; IRSET Laboratory, Inserm, UMR 1085, Rennes, France
| | - Josy Froger
- L'Institut du Thorax, CNRS, INSERM, Nantes Université, 44000 Nantes, France; Université Angers, SFR ICAT, 49000 Angers, France
| | | | - Maëva Durcin
- Université Angers, SFR ICAT, 49000 Angers, France
| | - Lionel Fizanne
- HIFIH, CHU Angers, Université Angers, SFR ICAT, 49000 Angers, France
| | - Valentine Ghesquière
- L'Institut du Thorax, CNRS, INSERM, Nantes Université, 44000 Nantes, France; Université Angers, SFR ICAT, 49000 Angers, France
| | - Xavier Prieur
- L'Institut du Thorax, CNRS, INSERM, Nantes Université, 44000 Nantes, France
| | - Julien Chaigneau
- HIFIH, CHU Angers, Université Angers, SFR ICAT, 49000 Angers, France
| | | | - Cédric Dray
- RESTORE, UMR 1301 Inserm, 5070 CNRS, Université Paul Sabatier, Toulouse, France
| | | | - Stéphanie Blandin
- CHU Nantes, CNRS, Inserm BioCore US16, SFR Bonamy, Nantes Université, 44000 Nantes, France
| | - Joëlle Dupont
- CNRS, IFCE, INRAE, PRC, Université de Tours, 37380 Nouzilly, France
| | - Pierre-Henri Ducluzeau
- CNRS, IFCE, INRAE, PRC, Université de Tours, 37380 Nouzilly, France; Service de Médecine Interne, Unité d'Endocrinologie Diabétologie et Nutrition, Centre Hospitalier Universitaire et Faculté de Médecine, Université de Tours, Tours, France
| | | | - Jérôme Boursier
- HIFIH, CHU Angers, Université Angers, SFR ICAT, 49000 Angers, France; CHU Angers, Angers, France
| | - Bertrand Cariou
- L'Institut du Thorax, CNRS, INSERM, Nantes Université, 44000 Nantes, France
| | - Soazig Le Lay
- L'Institut du Thorax, CNRS, INSERM, Nantes Université, 44000 Nantes, France; Université Angers, SFR ICAT, 49000 Angers, France.
| |
Collapse
|
4
|
Pépin JL, Bailly S, Texereau JB, Sonnet E, Picard S, Vergès B, Coffin Boutreux C, Arnault Ouary G, Kessler L, Guerci B, Anton Kuchly B, Fendri Gaied S, Cuperlier A, Voinot C, Derrien C, Dubois S, Lavergne F, Borel AL, Tamisier R, Benhamou PY. Prevalence of sleep apnoea in patients with type 1 diabetes and its association with comorbidities and diabetic complications: A French nationwide prospective study. Diabetes Obes Metab 2023; 25:1624-1631. [PMID: 36792920 DOI: 10.1111/dom.15015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/14/2022] [Revised: 01/31/2023] [Accepted: 02/07/2023] [Indexed: 02/17/2023]
Abstract
AIM To investigate sleep apnoea prevalence, factors influencing severity, and associations between sleep apnoea severity and micro-/macrovascular complications in a large population of patients with type 1 diabetes. MATERIALS AND METHODS This French multicentre prospective cohort study was conducted between July 2016 and June 2020. Adults with type 1 diabetes using an insulin pump were eligible. Home care provider nurses collected demographic and clinical data and set up oximetry to determine the oxygen desaturation index (ODI). No, mild-moderate and severe sleep apnoea were defined as ODI <15 events/h, 15 to <30 events/h and ≥30 events/h, respectively. Univariate and multivariate analyses were performed to identify factors associated with sleep apnoea, and associations between sleep apnoea severity and micro-/macrovascular complications were determined using logistic regression. RESULTS Of 769 participants, 12.4% and 3.4% had mild-to-moderate or severe sleep apnoea, respectively. Factors significantly associated with sleep apnoea on multivariate analysis were age, sex, body mass index (BMI) and hypertension. After adjustment for age, sex and BMI, presence of severe sleep apnoea was significantly associated with macrovascular complications (odds ratio vs. no sleep apnoea: 3.96 [95% confidence interval 1.43-11.11]; P < 0.01), while mild-to-moderate sleep apnoea was significantly associated with presence of diabetic retinopathy (odds ratio 2.09 [95% confidence interval 1.10-3.74]; P < 0.01). CONCLUSION Sleep apnoea is a significant comorbidity in patients with type 1 diabetes, especially with respect to diabetic complications. This highlights the need for sleep apnoea screening and management in these individuals.
Collapse
Affiliation(s)
- Jean-Louis Pépin
- Univ. Grenoble Alpes, INSERM U1300, CHU Grenoble Alpes, Grenoble, France
| | - Sébastien Bailly
- Univ. Grenoble Alpes, INSERM U1300, CHU Grenoble Alpes, Grenoble, France
| | - Joelle B Texereau
- Respiratory Physiology Unit, Department of Respiratory Medicine, Cochin Hospital, AP-HP/Université de Paris, Paris, France
- VitalAire, Air Liquide Health Care, Bagneux, France
| | | | | | | | | | | | - Laurence Kessler
- Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | | | | | | | | | | | | | | | | | - Anne Laure Borel
- Univ. Grenoble Alpes, INSERM U1300, CHU Grenoble Alpes, Grenoble, France
| | - Renaud Tamisier
- Univ. Grenoble Alpes, INSERM U1300, CHU Grenoble Alpes, Grenoble, France
| | | |
Collapse
|
5
|
Rakotoarisoa L, Weiss L, Lefebvre F, Porzio M, Ravoninjatovo B, Abely M, Boucher ID, Dubois S, Troussier F, Gilles R, Prevotat A, Kessler L. Comparison of Continuous Glucose Monitoring in Cystic Fibrosis Patients With or Without Pancreatic Exocrine Insufficiency. Horm Metab Res 2022; 54:407-412. [PMID: 35272389 DOI: 10.1055/a-1794-5496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
This study aimed to compare continuous glucose monitoring (CGM) in cystic fibrosis (CF) according to pancreatic exocrine status.CGM and oral glucose tolerance testing (OGTT) were realized annually over five years in people with CF (pwCF) aged≥10 years without cystic fibrosis-related diabetes (CFRD). CGM parameters in patients with normal glucose tolerance (NGT), impaired glucose tolerance (IGT), and newly diagnosed CFRD were compared according to presence of pancreatic sufficiency (PS) or insufficiency (PI).Overall, 547 OGTTs and 501 CGMs were performed in 147 CF patients, comprising 122 PI and 25 PS. In PS patients, 84% displayed NGT, 12% IGT, and 4% CFRD vs. 58%, 32%, and 10% (p=0.05) in PI. Among participants displaying normal OGTT, time in glucose range (70-140 mg/dl) was significantly increased, 97% (93, 99) vs. 92% (85, 96), p<0.001, and time above glucose range > 140 mg/dl significantly decreased, 1% (0, 2) % vs. 6% (2, 13), in patients with PS compared to those with PI. No significant differences were highlighted in patients with IGT.CGM revealed significant different glucose tolerance abnormalities in PI versus PS, which were undetected by standard 2-hour OGTT glucose.
Collapse
Affiliation(s)
- Luc Rakotoarisoa
- Department of Diabetology, University Hospital Strasbourg, Strasbourg, France
- Inserm UMR 1260, Regenerative Nanomedicine, University of Strasbourg, Strasbourg, France
| | - Laurence Weiss
- CRCM, University Hospital Strasbourg, Strasbourg, France
| | | | - Michele Porzio
- CRCM, University Hospital Strasbourg, Strasbourg, France
| | | | - Michel Abely
- CRCM, University Hospital Centre Reims, Reims, France
| | | | - Séverine Dubois
- Diabetology, University Hospital Centre Angers, Angers, France
| | | | | | - Anne Prevotat
- Allergology, Lille University Hospital Center, Lille, France
| | - Laurence Kessler
- Department of Diabetology, University Hospital Strasbourg, Strasbourg, France
- Inserm UMR 1260, Regenerative Nanomedicine, University of Strasbourg, Strasbourg, France
| |
Collapse
|
6
|
Natt N, Michael F, Michael H, Dubois S, Al Mazrou’i A. A213 ERCP-RELATED ADVERSE EVENTS IN PRIMARY SCLEROSING CHOLANGITIS: A SYSTEMATIC REVIEW & META-ANALYSIS. J Can Assoc Gastroenterol 2022. [PMCID: PMC8859312 DOI: 10.1093/jcag/gwab049.212] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Endoscopic retrograde cholangiopancreatography (ERCP) is a valuable diagnostic and therapeutic tool in primary sclerosing cholangitis (PSC). Although the complications of ERCP are well known in the general population, there is conflicting data regarding complications in patients with PSC. Factors that predict ERCP-related adverse events in PSC are also unclear.
Aims
To conduct a systematic review and meta-analyses to 1. compare ERCP-related adverse events in patients with and without PSC and 2. determine risk factors associated with ERCP-related adverse events in PSC.
Methods
A systematic search was conducted in Embase, PubMed and CENTRAL for studies published from January 1, 2000 to May 12, 2021. Eligible studies included adults with PSC undergoing ERCP and reported at least one ERCP-related adverse event (bleeding, perforation, pancreatitis, cholangitis) or risk factor associated with complications. Raw event rates for adverse events and risk factors were used to calculate odds ratios (ORs) which were then pooled using random-effects models.
Results
Four studies contributed to the first meta-analysis. There was a significant three-fold increase in the 30-day odds of cholangitis in PSC compared to those without PSC (4.3% vs. 2.0%; OR 3.26, 95% CI 1.08–9.90; p=0.037; I2=73.0%) (Figure 1). However, there were no significant differences in 30-day pancreatitis (4.2% vs. 3.4%; OR 0.89, 95% CI 0.26–3.07; p=0.851; I2=87.9%), bleeding (0.3% vs. 1.1%; OR 0.36, 95% CI 0.06–2.21; p=0.272; I2=50.3%), or perforation (0.7% vs. 0.5%; OR 1.19, 95% CI 0.40–3.51; p=0.752; I2=28.5%).
In a second meta-analysis, risk factors contributing to post-ERCP pancreatitis (PEP) in PSC were pooled from five studies. While female sex was not associated with PEP, accidental passage of wire into the pancreatic duct (OR 7.44, 95% CI 3.33–16.65; p<0.001; I2=65.0%) and biliary sphincterotomy (OR 4.80, 95% CI 1.92–12.03; p=0.001; I2=73.1%) were associated with higher PEP odds.
Conclusions
In the context of limited comparative data and study heterogeneity, PSC patients have higher odds of post-ERCP cholangitis despite the majority receiving antibiotics. Odds of bleeding, pancreatitis, and perforation were similar between groups. Accidental wire passage and biliary sphincterotomy increased odds of PEP, which helps identify higher-risk groups. Future studies should elucidate ERCP-related risks in PSC and guide preventive strategies.
Figure 1: 30-Day ERCP Complications
Funding Agencies
None
Collapse
Affiliation(s)
- N Natt
- Internal Medicine, Northern Ontario School of Medicine - East Campus, Sudbury, ON, Canada
| | - F Michael
- Internal Medicine, Northern Ontario School of Medicine - East Campus, Sudbury, ON, Canada
| | - H Michael
- McMaster University, Hamilton, ON, Canada
| | - S Dubois
- Northern Ontario School of Medicine, Thunder Bay, ON, Canada
| | - A Al Mazrou’i
- Internal Medicine, Northern Ontario School of Medicine - East Campus, Sudbury, ON, Canada
| |
Collapse
|
7
|
Reach G, Benarbia L, Benhamou PY, Delemer B, Dubois S, Gouet D, Guerci B, Jeandidier N, Lachgar K, Le Pape G, Leroy R, Masgnaux JH, Raclet P, Reznik Y, Riveline JP, Schaepelynck P, Vambergue A, Vergès B. An Unsafe/Safe Typology in People with Type 2 Diabetes: Bridging Patients' Expectations, Personality Traits, Medication Adherence, and Clinical Outcomes. Patient Prefer Adherence 2022; 16:1333-1350. [PMID: 35642243 PMCID: PMC9148599 DOI: 10.2147/ppa.s365398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/15/2022] [Accepted: 05/05/2022] [Indexed: 11/23/2022] Open
Abstract
BACKGROUND Support programs are provided to people with diabetes to help them manage their disease. However, adherence to and persistence in support programs are often low, making it difficult to demonstrate their effectiveness. AIM To identify the determinants of patients' perceived interest in diabetes support programs because it may be a powerful determinant of effective participation in such programs. PATIENTS AND METHODS An online study conducted in April 2021 in metropolitan France on 600 people with diabetes recruited from a consumer panel. A 64-item psychosocial questionnaire including a question asking to evaluate the helpfulness of a support program was used. Univariate, multivariate, and multiple correspondence analyses were performed. RESULTS The existence of a typology, known as Unsafe/Safe, was discovered, in which patients with type 2 diabetes respond in two distinct ways. Type U (unsafe) patients, who believe that a support program would be helpful, are more likely to be nonadherent to their treatment, have high hemoglobin A1c levels, have at least one diabetic complication, lack information regarding their disease and treatment, rate the burden of their disease and impairment of their quality of life as high, worry about their future, and are pessimistic. Type S (safe) patients have the opposite characteristics. Type U patients can be dichotomized into two broad classes: one in which they lack information regarding disease and treatment and the other in which alterations in the quality of life and burden of the disease predominate. Insulin-treated patients give more importance to the lack of information, whereas noninsulin-treated patients complain primarily about the burden of the disease and impairment of quality of life. CONCLUSION This study describes this new U/S typology, proposes a simple method based on a nine-item questionnaire to identify type U patients by calculating a Program Helpfulness Score described herein, and clarifies the nature of the intervention to be provided to them. This novel approach could be applied to other chronic diseases.
Collapse
Affiliation(s)
- Gérard Reach
- Health Education and Promotion Laboratory (LEPS EA 3412), Sorbonne Paris Nord University, Bobigny, France
- Correspondence: Gérard Reach, Health Education and Promotion Laboratory (LEPS EA 3412), Sorbonne Paris Nord University, 74 Rue Marcel Cachin, Bobigny Cedex, 93017, France, Tel + 33 (0)6 60 84 53 25, Email
| | | | - Pierre-Yves Benhamou
- Department of Endocrinology, Grenoble University Hospital; Grenoble Alpes University, INSERM U1055, LBFA, Grenoble, France
| | - Brigitte Delemer
- Service d’Endocrinologie – Diabète – Nutrition, CHU de Reims - Hôpital Robert Debré, and Université de Reims Champagne Ardenne, UFR Sciences Exactes Et Naturelles, Reims, France
| | - Séverine Dubois
- Department of Diabetology and Endocrinology, CHU Angers, Angers, France
| | - Didier Gouet
- Department of Diabetology and Endocrinology, Saint Louis Hospital, La Rochelle, France
| | - Bruno Guerci
- Department of Endocrinology, Diabetology and Nutrition, CHRU of Nancy, Brabois Hospital, and ILCV Lorraine University, Vandoeuvre-les-Nancy, France
| | - Nathalie Jeandidier
- Department of Endocrinology, Diabetes and Nutrition, Hôpitaux Universitaires de Strasbourg, and Université de Strasbourg, Strasbourg, France
| | - Karim Lachgar
- Department of Diabetology and Endocrinology, Centre Hospitalier Simone Veil, Eaubonne, France
| | | | - Rémy Leroy
- Private Medical Practice, Endocrinology and Diabetology, Lille, France
| | | | - Philippe Raclet
- Association Française des Diabétiques de Bourgogne Franche-Comté, Dijon, France
| | - Yves Reznik
- Department oEndocrinology and Diabetology, CHU Côte de Nacre, Caen, and University of Caen Basse-Normandie, Medical School, Caen, France
| | - Jean-Pierre Riveline
- Department of Diabetology and Endocrinology, Lariboisière Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France
- Unité INSERM U1138 Immunity and Metabolism in Diabetes, ImMeDiab Team, Centre de Recherches des Cordeliers, and Université de Paris, Paris, France
| | - Pauline Schaepelynck
- Department of Nutrition-Endocrinology-Metabolic Diseases, Pôle ENDO, APHM-Hôpital la Conception, Marseille, France
| | - Anne Vambergue
- Department of Diabetology, Endocrinology, Metabolism and Nutrition, CHU Lille, and University Hospital European Genomic Institute for Diabetes, Lille, France
| | - Bruno Vergès
- Department of Endocrinology-Diabetology,CHU Dijon, and University of Burgundy, INSERM LNC UMR1231, Dijon, France
| |
Collapse
|
8
|
Dubois S, Layese R, Languille L, Limal N, guillet S, Crickx E, Guillaud C, Lascu-Dubos G, Khellaf M, Mahevas M, Kini Matondo W, Michel M, Audureau E, Godeau B. Evaluation de la pertinence de la prescription des immunoglobulines par voie intraveineuse dans le purpura thrombopénique immunologique de l’adulte: résultat d’une étude pilote monocentrique portant sur 264 traitements. Rev Med Interne 2021. [DOI: 10.1016/j.revmed.2021.10.266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
9
|
Ali S, Malloci M, Safiedeen Z, Soleti R, Vergori L, Vidal-Gomez X, Besnard C, Dubois S, Le Lay S, Jerome B, Chevrollier A, Gagnadoux F, Simard G, Andriantsitohaina R, Martinez C. LPS-enriched small extracellular vesicles from metabolic syndrome patients trigger endothelial dysfunction by activation of TLR4. Archives of Cardiovascular Diseases Supplements 2021. [DOI: 10.1016/j.acvdsp.2021.04.079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
10
|
Ali S, Malloci M, Safiedeen Z, Soleti R, Vergori L, Vidal-Gómez X, Besnard C, Dubois S, Le Lay S, Boursier J, Chevrollier A, Gagnadoux F, Simard G, Andriantsitohaina R, Martinez MC. LPS-enriched small extracellular vesicles from metabolic syndrome patients trigger endothelial dysfunction by activation of TLR4. Metabolism 2021; 118:154727. [PMID: 33581132 DOI: 10.1016/j.metabol.2021.154727] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/09/2020] [Revised: 02/01/2021] [Accepted: 02/08/2021] [Indexed: 12/21/2022]
Abstract
BACKGROUND Metabolic syndrome (MetS) is characterized by a cluster of interconnected risk factors -hyperglycemia, dyslipidemia, hypertension and obesity- leading to an increased risk of cardiovascular events. Small extracellular vesicles (sEVs) can be considered as new biomarkers of different pathologies, and they are involved in intercellular communication. Here, we hypothesize that sEVs are implicated in MetS-associated endothelial dysfunction. METHODS Circulating sEVs of non-MetS (nMetS) subjects and MetS patients were isolated from plasma and characterized. Thereafter, sEV effects on endothelial function were analyzed by measuring nitric oxide (NO) and reactive oxygen species (ROS) production, and mitochondrial dynamic proteins on human endothelial aortic cells (HAoECs). RESULTS Circulating levels of sEVs positively correlated with anthropometric and biochemical parameters including visceral obesity, glycaemia, insulinemia, and dyslipidemia. Treatment of HAoECs with sEVs from MetS patients decreased NO production through the inhibition of the endothelial NO-synthase activity. Injection of MetS-sEVs into mice impaired endothelium-dependent relaxation induced by acetylcholine. Furthermore, MetS-sEVs increased DHE and MitoSox-associated fluorescence in HAoECs, reflecting enhanced cytosolic and mitochondrial ROS production which was not associated with mitochondrial biogenesis or dynamic changes. MetS patients displayed elevated circulating levels of LPS in plasma, and, at least in part, it was associated to circulating sEVs. Pharmacological inhibition and down-regulation of TLR4, as well as sEV-carried LPS neutralization, results in a substantial decrease of ROS production induced by MetS-sEVs. CONCLUSION These results evidence sEVs from MetS patients as potential new biomarkers for this syndrome, and TLR4 pathway activation by sEVs provides a link between the endothelial dysfunction and metabolic disturbances described in MetS.
Collapse
Affiliation(s)
- Sakina Ali
- SOPAM, U1063, INSERM, UNIV Angers, SFR ICAT, Angers, France
| | - Marine Malloci
- SOPAM, U1063, INSERM, UNIV Angers, SFR ICAT, Angers, France
| | | | | | - Luisa Vergori
- SOPAM, U1063, INSERM, UNIV Angers, SFR ICAT, Angers, France
| | | | | | - Séverine Dubois
- SOPAM, U1063, INSERM, UNIV Angers, SFR ICAT, Angers, France; Centre Hospitalo-Universitaire d'Angers, France
| | - Soazig Le Lay
- SOPAM, U1063, INSERM, UNIV Angers, SFR ICAT, Angers, France
| | | | - Arnaud Chevrollier
- Centre Hospitalo-Universitaire d'Angers, France; Institut MITOVASC, CNRS 6015, INSERM U1083, UNIV Angers, SFR ICAT, Angers, France
| | - Frédéric Gagnadoux
- SOPAM, U1063, INSERM, UNIV Angers, SFR ICAT, Angers, France; Centre Hospitalo-Universitaire d'Angers, France
| | - Gilles Simard
- SOPAM, U1063, INSERM, UNIV Angers, SFR ICAT, Angers, France; Centre Hospitalo-Universitaire d'Angers, France
| | - Ramaroson Andriantsitohaina
- SOPAM, U1063, INSERM, UNIV Angers, SFR ICAT, Angers, France; Centre Hospitalo-Universitaire d'Angers, France
| | - M Carmen Martinez
- SOPAM, U1063, INSERM, UNIV Angers, SFR ICAT, Angers, France; Centre Hospitalo-Universitaire d'Angers, France.
| |
Collapse
|
11
|
Monin L, Dubois S, Reenaers C, Van Kemseke C, Latour P, Van Daele D, Vieujean S, Seidel L, Louis E. Ustekinumab in bio-naïve and bio-failure Crohn's disease patients: Results from a « real-life » monocentric cohort. Dig Liver Dis 2021; 53:72-78. [PMID: 33221330 DOI: 10.1016/j.dld.2020.10.040] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/21/2020] [Revised: 10/29/2020] [Accepted: 10/31/2020] [Indexed: 12/11/2022]
Abstract
BACKGROUND The pivotal clinical trials have largely demonstrated the efficacy and safety of ustekinumab in Crohn's disease. Real-life cohorts published so far only include very few bio-naïve patients. This study assesses effectiveness and safety of ustekinumab in bio-naïve and bio-failure patients treated with ustekinumab in routine practice and look for predictors of response. METHODS We performed a retrospective monocentric study. Initial response was assessed by maintenance therapy beyond week 16. Sustained response was assessed by the continuation or cessation of therapy over time for another reason than stopping in sustained remission. Treatment persistence was assessed by Kaplan Meier curves and predictors of treatment persistence were studied by univariate and multivariate Cox model. RESULTS Out of 156 recorded patients, three patients were still in their induction phase at time of analysis and 5 patients were lost to follow-up, leaving 148 patients for clinical effectiveness analyses, including 35 bio-naïve when starting ustekinumab. A maintenance therapy was initiated in 79.7%. At one year, the probability to be still treated with ustekinumab was 73.8%. Treatment cessation increased with smoking in multivariate analysis. Previous biologic failure (as a whole), CRP and fecal calprotectin baseline levels did not influence initial response and treatment persistence. CONCLUSION A large proportion of CD patients initially respond to ustekinumab and continue this treatment beyond one year. Treatment persistence is as high in bio-failure as in bio-naïve patients.
Collapse
Affiliation(s)
- L Monin
- Department of Gastroenterology, University Hospital, CHU Liège, Belgium
| | - S Dubois
- Department of Gastroenterology, University Hospital, CHU Liège, Belgium
| | - C Reenaers
- Department of Gastroenterology, University Hospital, CHU Liège, Belgium
| | - C Van Kemseke
- Department of Gastroenterology, University Hospital, CHU Liège, Belgium
| | - P Latour
- Department of Gastroenterology, University Hospital, CHU Liège, Belgium
| | - D Van Daele
- Department of Gastroenterology, University Hospital, CHU Liège, Belgium
| | - S Vieujean
- Department of Gastroenterology, University Hospital, CHU Liège, Belgium
| | - L Seidel
- Department of Biostatistics, University Hospital, CHU Liège, Belgium
| | - E Louis
- Department of Gastroenterology, University Hospital, CHU Liège, Belgium.
| |
Collapse
|
12
|
Perdomo L, Vidal-Gómez X, Soleti R, Vergori L, Duluc L, Chwastyniak M, Bisserier M, Le Lay S, Villard A, Simard G, Meilhac O, Lezoualc'h F, Khantalin I, Veerapen R, Dubois S, Boursier J, Henni S, Gagnadoux F, Pinet F, Andriantsitohaina R, Martínez MC. Large Extracellular Vesicle-Associated Rap1 Accumulates in Atherosclerotic Plaques, Correlates With Vascular Risks and Is Involved in Atherosclerosis. Circ Res 2020; 127:747-760. [PMID: 32539601 DOI: 10.1161/circresaha.120.317086] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
RATIONALE Metabolic syndrome (MetS) is a cluster of interrelated risk factors for cardiovascular diseases and atherosclerosis. Circulating levels of large extracellular vesicles (lEVs), submicrometer-sized vesicles released from plasma membrane, from MetS patients were shown to induce endothelial dysfunction, but their role in early stage of atherosclerosis and on vascular smooth muscle cells (SMC) remain to be fully elucidated. OBJECTIVE To determine the mechanisms by which lEVs lead to the progression of atherosclerosis in the setting of MetS. METHODS AND RESULTS Proteomic analysis revealed that the small GTPase, Rap1 was overexpressed in lEVs from MetS patients compared with those from non-MetS subjects. Rap1 was in GTP-associated active state in both types of lEVs, and Rap1-lEVs levels correlated with increased cardiovascular risks, including stenosis. MetS-lEVs, but not non-MetS-lEVs, increased Rap1-dependent endothelial cell permeability. MetS-lEVs significantly promoted migration and proliferation of human aortic SMC and increased expression of proinflammatory molecules and activation of ERK (extracellular signal-regulated kinase) 5/p38 pathways. Neutralization of Rap1 by specific antibody or pharmacological inhibition of Rap1 completely prevented the effects of lEVs from MetS patients. High-fat diet-fed ApoE-/- mice displayed an increased expression of Rap1 both in aortas and circulating lEVs. lEVs accumulated in plaque atherosclerotic lesions depending on the progression of atherosclerosis. lEVs from high-fat diet-fed ApoE-/- mice, but not those from mice fed with a standard diet, enhanced SMC proliferation. Human atherosclerotic lesions were enriched in lEVs expressing Rap1. CONCLUSIONS These data demonstrate that Rap1 carried by MetS-lEVs participates in the enhanced SMC proliferation, migration, proinflammatory profile, and activation of ERK5/p38 pathways leading to vascular inflammation and remodeling, and atherosclerosis. These results highlight that Rap1 carried by MetS-lEVs may be a novel determinant of diagnostic value for cardiometabolic risk factors and suggest Rap1 as a promising therapeutic target against the development of atherosclerosis. Graphical Abstract: A graphical abstract is available for this article.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Animals
- Atherosclerosis/blood
- Atherosclerosis/metabolism
- Atherosclerosis/pathology
- Case-Control Studies
- Cell Movement
- Cell Proliferation
- Cells, Cultured
- Disease Models, Animal
- Endothelial Cells/metabolism
- Endothelial Cells/pathology
- Extracellular Vesicles/metabolism
- Female
- Humans
- Male
- Mice, Inbred C57BL
- Mice, Knockout, ApoE
- Middle Aged
- Mitogen-Activated Protein Kinase 7/metabolism
- Muscle, Smooth, Vascular/metabolism
- Muscle, Smooth, Vascular/pathology
- Myocytes, Smooth Muscle/metabolism
- Myocytes, Smooth Muscle/pathology
- Permeability
- Phosphorylation
- Plaque, Atherosclerotic
- Prognosis
- Proteomics
- Risk Assessment
- Risk Factors
- Signal Transduction
- p38 Mitogen-Activated Protein Kinases/metabolism
- rap GTP-Binding Proteins
- rap1 GTP-Binding Proteins/metabolism
Collapse
Affiliation(s)
- Liliana Perdomo
- From the SOPAM, U1063, INSERM, UNIV Angers, SFR ICAT, France (L.P., X.V.-G., R.S., L.V., L.D., S.L.L., A.V., G.S., S.D., F.G., R.A., M.C.M.)
| | - Xavier Vidal-Gómez
- From the SOPAM, U1063, INSERM, UNIV Angers, SFR ICAT, France (L.P., X.V.-G., R.S., L.V., L.D., S.L.L., A.V., G.S., S.D., F.G., R.A., M.C.M.)
| | - Raffaella Soleti
- From the SOPAM, U1063, INSERM, UNIV Angers, SFR ICAT, France (L.P., X.V.-G., R.S., L.V., L.D., S.L.L., A.V., G.S., S.D., F.G., R.A., M.C.M.)
| | - Luisa Vergori
- From the SOPAM, U1063, INSERM, UNIV Angers, SFR ICAT, France (L.P., X.V.-G., R.S., L.V., L.D., S.L.L., A.V., G.S., S.D., F.G., R.A., M.C.M.)
| | - Lucie Duluc
- From the SOPAM, U1063, INSERM, UNIV Angers, SFR ICAT, France (L.P., X.V.-G., R.S., L.V., L.D., S.L.L., A.V., G.S., S.D., F.G., R.A., M.C.M.)
| | - Maggy Chwastyniak
- Université de Lille, Inserm, CHU Lille, Institute Pasteur De Lille, U1167 - RID-AGE, Lille, France (M.C., F.P.)
| | - Malik Bisserier
- Inserm, UMR-1048, Institut Des Maladies Métaboliques et Cardiovasculaires, Toulouse, France (M.B., F.L.)
| | - Soazig Le Lay
- From the SOPAM, U1063, INSERM, UNIV Angers, SFR ICAT, France (L.P., X.V.-G., R.S., L.V., L.D., S.L.L., A.V., G.S., S.D., F.G., R.A., M.C.M.)
| | - Alexandre Villard
- From the SOPAM, U1063, INSERM, UNIV Angers, SFR ICAT, France (L.P., X.V.-G., R.S., L.V., L.D., S.L.L., A.V., G.S., S.D., F.G., R.A., M.C.M.)
| | - Gilles Simard
- From the SOPAM, U1063, INSERM, UNIV Angers, SFR ICAT, France (L.P., X.V.-G., R.S., L.V., L.D., S.L.L., A.V., G.S., S.D., F.G., R.A., M.C.M.)
| | - Olivier Meilhac
- DéTROI, INSERM U1188, Université de La Réunion, France (O.M.)
| | - Frank Lezoualc'h
- Inserm, UMR-1048, Institut Des Maladies Métaboliques et Cardiovasculaires, Toulouse, France (M.B., F.L.)
| | | | - Reuben Veerapen
- Clinique Sainte-Clotilde, Groupe Clinifutur, Sainte-Clotilde, France (R.V.)
| | - Séverine Dubois
- From the SOPAM, U1063, INSERM, UNIV Angers, SFR ICAT, France (L.P., X.V.-G., R.S., L.V., L.D., S.L.L., A.V., G.S., S.D., F.G., R.A., M.C.M.)
- CHU d'Angers, France (S.D., J.B., S.H., F.G., R.A., M.C.M.)
| | | | - Samir Henni
- CHU d'Angers, France (S.D., J.B., S.H., F.G., R.A., M.C.M.)
| | - Frédéric Gagnadoux
- From the SOPAM, U1063, INSERM, UNIV Angers, SFR ICAT, France (L.P., X.V.-G., R.S., L.V., L.D., S.L.L., A.V., G.S., S.D., F.G., R.A., M.C.M.)
- CHU d'Angers, France (S.D., J.B., S.H., F.G., R.A., M.C.M.)
| | - Florence Pinet
- Université de Lille, Inserm, CHU Lille, Institute Pasteur De Lille, U1167 - RID-AGE, Lille, France (M.C., F.P.)
| | - Ramaroson Andriantsitohaina
- From the SOPAM, U1063, INSERM, UNIV Angers, SFR ICAT, France (L.P., X.V.-G., R.S., L.V., L.D., S.L.L., A.V., G.S., S.D., F.G., R.A., M.C.M.)
- CHU d'Angers, France (S.D., J.B., S.H., F.G., R.A., M.C.M.)
| | - M Carmen Martínez
- From the SOPAM, U1063, INSERM, UNIV Angers, SFR ICAT, France (L.P., X.V.-G., R.S., L.V., L.D., S.L.L., A.V., G.S., S.D., F.G., R.A., M.C.M.)
- CHU d'Angers, France (S.D., J.B., S.H., F.G., R.A., M.C.M.)
| |
Collapse
|
13
|
Carpentier C, Dubois S, Mohammedi K, Belhatem N, Bouhanick B, Rohmer V, Briet C, Bumbu A, Hadjadj S, Roussel R, Potier L, Velho G, Marre M. Glycosuria amount in response to hyperglycaemia and risk for diabetic kidney disease and related events in Type 1 diabetic patients. Nephrol Dial Transplant 2020; 34:1731-1738. [PMID: 29982607 DOI: 10.1093/ndt/gfy197] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2018] [Accepted: 05/15/2018] [Indexed: 01/16/2023] Open
Abstract
BACKGROUND Hyperglycaemia impairs tubulo-glomerular feedback. We tested whether variable tubulo-glomerular feedback during hyperglycaemia contributes to renal risk heterogeneity seen in Type 1 diabetes. METHODS During the period 1990-92, we studied the tubulo-glomerular feedback in Type 1 diabetic patients at high or low renal risk [21 of 54 with glomerular hyperfiltration and/or microalbuminuria against 11 of 55 with normal glomerular filtration rate (GFR) and urinary albumin despite uncontrolled diabetes]. The GFR, effective renal plasma flow, mean arterial pressure and fractional reabsorptions of glucose, osmols, sodium and lithium were measured sequentially during normo- and hyperglycaemia. All patients were followed up until 2016 for incident proteinuria, estimated GFR <60 mL/min/1.73 m2, doubling of serum creatinine, end-stage renal disease or all-cause death. RESULTS Glycaemia increased from 6.1 ± 1.3 to 15.1 ± 1.9 mmol/L in both high-risk and low-risk patients. Glycosuria was lower in the high- versus low-risk patients: 0.34 ± 0.25 versus 0.64 ± 0.44 mmol/min (P = 0.03). Both groups displayed similar kidney function during normoglycaemia. Hyperglycaemia increased more importantly GFR and fractional reabsorptions, and pre-glomerular vasodilatation in the high- than in the low-risk patients (all P < 0.05). Over 21 years, 31.5% high- versus 12.7% low-risk patients developed endpoints (adjusted P = 0.006). In a multi-adjusted survival analysis of patients having undergone renal tests, each 0.10 mmol/min glycosuria during hyperglycaemia reduced the outcome risk by 0.72 (95% confidence interval 0.49-0.97, P = 0.03). CONCLUSIONS Reduced tubulo-glomerular feedback and glycosuria during hyperglycaemia indicate high renal risk for Type 1 diabetic patients. Inter-individual variability in tubulo-glomerular feedback activity determines renal risk in Type 1 diabetes.
Collapse
Affiliation(s)
- Charlyne Carpentier
- Centre Hospitalier Universitaire d'Angers, Service EDN, Angers, France.,INSERM, UMRS 1063, SOPAM, Université d'Angers, Angers, France
| | - Séverine Dubois
- Centre Hospitalier Universitaire d'Angers, Service EDN, Angers, France.,INSERM, UMRS 1063, SOPAM, Université d'Angers, Angers, France
| | - Kamel Mohammedi
- Hôpital Haut-Lévêque, Service d'Endocrinologie, Diabétologie, Nutrition, Bordeaux, France.,Université de Bordeaux, Faculté de Médecine Paul Broca, Bordeaux, France.,Centre de Recherche INSERM-Université de Bordeaux U1219 'Bordeaux Population Health', Bordeaux, France
| | - Narimène Belhatem
- Assistance Publique-Hôpitaux de Paris (AP-HP), Bichat Hospital, DHU FIRE, Department of Diabetology, Endocrinology and Nutrition, Paris, France
| | - Béatrice Bouhanick
- Centre Hospitalier Universitaire Rangueil, Service d'Hypertension et de Thérapeutique, TSA, Toulouse, France.,INSERM UMRS 1027, Université Toulouse 3, Toulouse, France
| | - Vincent Rohmer
- Centre Hospitalier Universitaire d'Angers, Service EDN, Angers, France.,INSERM, UMRS 1063, SOPAM, Université d'Angers, Angers, France
| | - Claire Briet
- Centre Hospitalier Universitaire d'Angers, Service EDN, Angers, France.,INSERM, UMRS 1063, SOPAM, Université d'Angers, Angers, France
| | - Anisoara Bumbu
- Assistance Publique-Hôpitaux de Paris (AP-HP), Bichat Hospital, DHU FIRE, Department of Diabetology, Endocrinology and Nutrition, Paris, France
| | - Samy Hadjadj
- INSERM, CIC 0802, Poitiers, France.,Université de Poitiers, UFR de Médecine et Pharmacie, Poitiers, France.,INSERM, Research Unit 1082, Poitiers, France.,Centre Hospitalier Universitaire de Poitiers, Department of Endocrinology and Diabetology, Poitiers, France
| | - Ronan Roussel
- Assistance Publique-Hôpitaux de Paris (AP-HP), Bichat Hospital, DHU FIRE, Department of Diabetology, Endocrinology and Nutrition, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, UFR de Médecine, Paris, France.,Inserm Research Unit 1138, Centre de Recherche des Cordeliers, Paris, France
| | - Louis Potier
- Assistance Publique-Hôpitaux de Paris (AP-HP), Bichat Hospital, DHU FIRE, Department of Diabetology, Endocrinology and Nutrition, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, UFR de Médecine, Paris, France.,Inserm Research Unit 1138, Centre de Recherche des Cordeliers, Paris, France
| | - Gilberto Velho
- Inserm Research Unit 1138, Centre de Recherche des Cordeliers, Paris, France
| | - Michel Marre
- Assistance Publique-Hôpitaux de Paris (AP-HP), Bichat Hospital, DHU FIRE, Department of Diabetology, Endocrinology and Nutrition, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, UFR de Médecine, Paris, France.,Inserm Research Unit 1138, Centre de Recherche des Cordeliers, Paris, France
| |
Collapse
|
14
|
Suteau V, Saulnier PJ, Wargny M, Gonder-Frederick L, Gand E, Chaillous L, Allix I, Dubois S, Bonnet F, Leguerrier AM, Fradet G, Delcourt Crespin I, Kerlan V, Gouet D, Perlemoine C, Ducluzeau PH, Pichelin M, Ragot S, Hadjadj S, Cariou B, Briet C. Association between sleep disturbances, fear of hypoglycemia and psychological well-being in adults with type 1 diabetes mellitus, data from cross-sectional VARDIA study. Diabetes Res Clin Pract 2020; 160:107988. [PMID: 31866527 DOI: 10.1016/j.diabres.2019.107988] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/16/2019] [Revised: 12/06/2019] [Accepted: 12/17/2019] [Indexed: 02/01/2023]
Abstract
AIM To assess the relationship between sleep quality, fear of hypoglycemia, glycemic variability and psychological well-being in type 1 diabetes mellitus. METHODS Our data were provided by the VARDIA Study, a multicentric cross-sectional study conducted between June and December 2015. Sleep characteristics were assessed by the Pittsburgh Sleep Quality Index (PSQI). Fear of hypoglycemia and psychological well-being were measured with the Hypoglycemia Fear Survey version II (HFS-II) and the Hospital Anxiety and Depression Scale (HADS), respectively. Glycemic variability (GV) was determined using the CV of three 7-point self-monitoring blood glucose profiles and the mean amplitude of glycemic excursion (MAGE). RESULTS 315 patients were eligible for PSQI questionnaire analysis: 54% women, mean age 47 ± 15, mean diabetes duration of 24 ± 13 years, HbA1c of 7.6 ± 0.9% (60 ± 7,5mmol/mol). Average PSQI score was 6.0 ± 3.3 and 59.8% of the patients had a PSQI score > 5. HFS-II score and HADS were significantly higher among "poor" sleepers (p < 0.0001) and PSQI score was positively associated with HADS (β = 0.22; 95% CI = 0.08;0.35). GV evaluated by CV or MAGE did not differ between "poor" and "good" sleepers (p = 0.28 and 0.54, respectively). CONCLUSIONS Adult patients with type 1 diabetes have sleep disturbances which correlate with psychological well-being. This study suggests that psychological management can be a target to improve sleep quality in adults with type 1 diabetes mellitus.
Collapse
Affiliation(s)
- Valentine Suteau
- Institut MITOVASC, UMR CNRS 6015, INSERM 1083, Université d'Angers, 3 rue Roger Amsler, 49100 Angers, France; Diabetes Department, CHU d'Angers, 4 rue Larrey, 49100 Angers, France.
| | - Pierre-Jean Saulnier
- Clinical Investigation Center CIC1402, CHU de Poitiers 2 rue de la Miletrie, 86000 Poitiers, France; CHU Poitiers, Diabetes Department, 2 rue de la Milétrie, CS 90577, 86000 Poitiers, France.
| | - Matthieu Wargny
- L'institut du thorax, CHU Nantes, INSERM CIC1413, Hôpital Nord Laennec Boulevard Jacques-Monod Saint-Herblain, 44093 Nantes Cedex 1, France.
| | | | - Elise Gand
- Clinical Investigation Center CIC1402, CHU de Poitiers 2 rue de la Miletrie, 86000 Poitiers, France.
| | - Lucy Chaillous
- L'institut du thorax, CHU Nantes, INSERM CIC1413, Hôpital Nord Laennec Boulevard Jacques-Monod Saint-Herblain, 44093 Nantes Cedex 1, France.
| | - Ingrid Allix
- Diabetes Department, CHU d'Angers, 4 rue Larrey, 49100 Angers, France.
| | - Séverine Dubois
- Diabetes Department, CHU d'Angers, 4 rue Larrey, 49100 Angers, France; INSERM U1063, Oxidative Stress and Metabolic Pathologies, Université d'Angers, CHU Angers, 4 Rue Larrey, 49933 Angers Cedex 9, France.
| | - Fabrice Bonnet
- CHU Rennes, Diabetes Department, 2 rue Henri Le Guilloux, 35033 Rennes Cedex 9, France.
| | - Anne-Marie Leguerrier
- CHU Rennes, Diabetes Department, 2 rue Henri Le Guilloux, 35033 Rennes Cedex 9, France
| | - Gerard Fradet
- CH Départemental Vendée, Boulevard Stéphane Moreau, 85000 La Roche-sur-Yon, France.
| | | | - Véronique Kerlan
- CHU Brest, Diabetes Department, Hôpital de La Cavale Blanche, Boulevard Tanguy Prigent, 29200 Brest, France.
| | - Didier Gouet
- CH La Rochelle, Diabetes Department, Rue du docteur Schweitzer, 17019 La Rochelle Cedex, France.
| | - Caroline Perlemoine
- CH Bretagne Sud, Diabetes Department, 5 Avenue Choiseul, 56322 Lorient, France.
| | | | - Matthieu Pichelin
- L'institut du thorax, CHU Nantes, INSERM CIC1413, Hôpital Nord Laennec Boulevard Jacques-Monod Saint-Herblain, 44093 Nantes Cedex 1, France.
| | - Stéphanie Ragot
- Clinical Investigation Center CIC1402, CHU de Poitiers 2 rue de la Miletrie, 86000 Poitiers, France.
| | - Samy Hadjadj
- Clinical Investigation Center CIC1402, CHU de Poitiers 2 rue de la Miletrie, 86000 Poitiers, France; CHU Poitiers, Diabetes Department, 2 rue de la Milétrie, CS 90577, 86000 Poitiers, France.
| | - Bertrand Cariou
- L'institut du thorax, CHU Nantes, INSERM CIC1413, Hôpital Nord Laennec Boulevard Jacques-Monod Saint-Herblain, 44093 Nantes Cedex 1, France.
| | - Claire Briet
- Institut MITOVASC, UMR CNRS 6015, INSERM 1083, Université d'Angers, 3 rue Roger Amsler, 49100 Angers, France; Diabetes Department, CHU d'Angers, 4 rue Larrey, 49100 Angers, France.
| |
Collapse
|
15
|
Trzepizur W, Boursier J, Berréhare A, Le Vaillant M, Andriantsitohaina R, Ducluzeau PH, Dubois S, Henni S, Abraham P, Calès P, Aubé C, Paisant A, Gagnadoux F. Obstructive sleep apnoea severity and liver steatosis measured by magnetic resonance imaging. Eur Respir J 2020; 55:13993003.01514-2019. [PMID: 31649063 DOI: 10.1183/13993003.01514-2019] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2019] [Accepted: 09/11/2019] [Indexed: 01/21/2023]
Affiliation(s)
- Wojciech Trzepizur
- Département de Pneumologie et Médecine du Sommeil, Centre Hospitalier Universitaire, Angers, France .,INSERM UMR 1063 SOPAM, Université d'Angers, Angers, France
| | - Jérôme Boursier
- Département d'Hépato-Gastroentérologie, Centre Hospitalier Universitaire, Angers, France.,HIFIH, EA3859, Université d'Angers, Angers, France
| | - Anna Berréhare
- Département de Pneumologie et Médecine du Sommeil, Centre Hospitalier Universitaire, Angers, France
| | - Marc Le Vaillant
- Institut de Recherche en Santé Respiratoire des Pays de la Loire, Beaucouzé, France
| | | | - Pierre-Henri Ducluzeau
- Unité d'Endocrinologie-Diabétologie-Nutrition, Pole de Médecine, Centre Hospitalier Universitaire, Tours, France
| | - Séverine Dubois
- INSERM UMR 1063 SOPAM, Université d'Angers, Angers, France.,Département d'Endocrinologie, Diabétologie et Nutrition, Centre Hospitalier Universitaire, Angers, France
| | - Samir Henni
- Service de Médecine Vasculaire, Centre Hospitalier Universitaire, Angers, France.,Institut MITOVASC, UMR CNRS 6015, INSERM 1083, Université d'Angers, Angers, France
| | - Pierre Abraham
- Service de Médecine Vasculaire, Centre Hospitalier Universitaire, Angers, France.,Institut MITOVASC, UMR CNRS 6015, INSERM 1083, Université d'Angers, Angers, France
| | - Paul Calès
- Département d'Hépato-Gastroentérologie, Centre Hospitalier Universitaire, Angers, France.,HIFIH, EA3859, Université d'Angers, Angers, France
| | - Christophe Aubé
- HIFIH, EA3859, Université d'Angers, Angers, France.,Département de Radiologie, Centre Hospitalier Universitaire, Angers, France
| | - Anita Paisant
- HIFIH, EA3859, Université d'Angers, Angers, France.,Département de Radiologie, Centre Hospitalier Universitaire, Angers, France
| | - Frédéric Gagnadoux
- Département de Pneumologie et Médecine du Sommeil, Centre Hospitalier Universitaire, Angers, France.,INSERM UMR 1063 SOPAM, Université d'Angers, Angers, France
| | | |
Collapse
|
16
|
Ziegler D, Doz F, Geoerger B, Dubois S, Grilley-Olson J, van Tilburg C, Italiano A, Lissat A, Kang JH, Tahara M, Boni V, Perreault S, Capra M, Nanda S, Brega N, Holynskyj A, Hong D, Hyman D, Drilon A. Activity of larotrectinib in TRK fusion cancer patients with primary central nervous system tumours. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz431.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
17
|
Hyman D, Tan D, van Tilburg C, Albert C, Geoerger B, Farago A, Laetsch T, Kummar S, Doz F, Lassen U, Dubois S, McDermott R, Mascarenhas L, Berlin J, Rudzinski E, Nanda S, Childs B, Drilon A, Hong D. Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz431.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Ali S, Vergori L, Soleti R, Le Lay S, Simard G, Dubois S, Andriantsitohaina R, Martinez M. Circulating exosomes from metabolic syndrome patients induce insulin resistance in human hepatocytes but not in human endothelial cells. Archives of Cardiovascular Diseases Supplements 2019. [DOI: 10.1016/j.acvdsp.2019.02.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
19
|
Dubois S, Leguelinel-Blache G, Thibault M, Janès A, Bussières JF. [Pharmaceutical analysis of medication orders in health care facilities: A France-Quebec comparison]. Ann Pharm Fr 2019; 77:241-249. [PMID: 30799017 DOI: 10.1016/j.pharma.2019.01.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2018] [Revised: 12/17/2018] [Accepted: 01/15/2019] [Indexed: 10/27/2022]
Abstract
OBJECTIVES The pharmaceutical analysis of drug prescriptions is one of the key steps in the drug circuit. This mandatory regulatory practice in France and Quebec is based on national standards. The main objective of this work was to compare the practical methods of pharmaceutical analysis performed in French and Quebec university hospitals. METHODS This is a prospective comparative survey conducted in 2 French and Quebec university hospital centres among pharmacists and pharmacy residents. RESULTS The response rate to the survey was 60% (45/75). Between 16 and 22 elements were deemed necessary to structure the centralized, decentralized or mixed pharmaceutical analysis. The chronological ranking of these elements was comparable between the French and Quebec participants. All participants were in favour of the development of initial and continuing training in pharmaceutical analysis. Finally, the majority of participants were against using individual pharmaceutical analysis performance indicators to optimize the process (82%; 37/45). CONCLUSIONS The French-Quebec practice of prescription analysis by a ward-pharmacist complies with national standards. The main differences in the practice of pharmaceutical analysis are related to the types of organization, the tools available and the length of time pharmacists have been deployed in care units in France and Quebec.
Collapse
Affiliation(s)
- S Dubois
- Cité sanitaire Georges Charpak, 11, boulevard Georges-Charpak, BP 414, 44606 Saint-Nazaire cedex, France
| | - G Leguelinel-Blache
- CHU de Nîmes, 4, rue du Professeur-Robert-Debré, 30029 Nîmes, France; Faculté de pharmacie, université de Montpellier, 15, avenue Charles-Flahault, BP 14491, 34093 Montpellier cedex 5, France
| | - M Thibault
- CHU Sainte-Justine, Montréal (Québec), Canada
| | - A Janès
- CHU Carémeau, 30029 Nîmes cedex 9, France
| | - J-F Bussières
- Unité de recherche en pratique pharmaceutique, département de pharmacie, CHU Sainte-Justine, Montréal (Québec), Canada; Faculté de pharmacie, université de Montréal, Montréal (Québec), Canada.
| |
Collapse
|
20
|
Maghin F, Silacci P, Ampuero S, Dubois S, Bee G. PSIX-16 Effect of supplementing hydrolysable tannins to a grower-finisher diet containing divergent PUFA levels on growth performance and boar taint levels in the backfat of entire males. J Anim Sci 2018. [DOI: 10.1093/jas/sky404.612] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- F Maghin
- Università degli Studi di Milano,Milan, Milan, Italy
| | | | | | | | - G Bee
- Agroscope,Posieux, Switzerland
| |
Collapse
|
21
|
Amosse J, Durcin M, Malloci M, Vergori L, Fleury A, Gagnadoux F, Dubois S, Simard G, Boursier J, Hue O, Martinez MC, Andriantsitohaina R, Le Lay S. Phenotyping of circulating extracellular vesicles (EVs) in obesity identifies large EVs as functional conveyors of Macrophage Migration Inhibitory Factor. Mol Metab 2018; 18:134-142. [PMID: 30473096 PMCID: PMC6309717 DOI: 10.1016/j.molmet.2018.10.001] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/24/2018] [Revised: 09/24/2018] [Accepted: 10/02/2018] [Indexed: 01/08/2023] Open
Abstract
Objective Obesity-associated metabolic dysfunctions are linked to dysregulated production of adipokines. Accumulating evidence suggests a role for fat-derived extracellular vesicles (EVs) in obesity-metabolic disturbances. Since EVs convey numerous proteins we aimed to evaluate their contribution in adipokine secretion. Methods Plasma collected from metabolic syndrome patients were used to isolate EV subtypes, namely microvesicles (MVs) and exosomes (EXOs). Numerous soluble factor concentrations were measured successively on total, MV- and EXO-depleted plasma by multiplexed immunoassays. Results Circulating MVs and EXOs were significantly increased with BMI, supporting a role of EVs as metabolic relays in obesity. Obesity was associated with dysregulated soluble factor production. Sequential depletion of plasma MVs and EXOs did not modify plasma levels of these molecules, with the exception of Macrophage Migration Inhibitory Factor (MIF). Half of plasma MIF circulated within MVs, and this MV secretory pathway was conserved over different MIF-producing cells. Although MV-associated MIF triggered rapid ERK1/2 activation in macrophages, these functional MV-MIF effects specifically relied on MIF tautomerase activity. Conclusion Our results emphasize the importance of reconsidering MIF-metabolic actions with regard to its MV-associated form and opening new EV-based strategies for therapeutic MIF approaches. Plasma EV subtypes are significantly increased with obesity. Plasma EV subtypes carry adipokines. MV (large EV subtype) constitute a major secretory pathway for MIF. MV-associated MIF transduces metabolic responses through its tautomerase activity.
Collapse
Affiliation(s)
- Jérémy Amosse
- INSERM U1063, Oxidative Stress and Metabolic Pathologies, Angers University, France
| | - Maëva Durcin
- INSERM U1063, Oxidative Stress and Metabolic Pathologies, Angers University, France; Adaptation to Tropical Climate and Exercise Laboratory, EA3596, University of the French West Indies, Pointe-à-Pitre, Guadeloupe, France
| | - Marine Malloci
- INSERM U1063, Oxidative Stress and Metabolic Pathologies, Angers University, France
| | - Luisa Vergori
- INSERM U1063, Oxidative Stress and Metabolic Pathologies, Angers University, France
| | - Audrey Fleury
- INSERM U1063, Oxidative Stress and Metabolic Pathologies, Angers University, France
| | - Frédéric Gagnadoux
- INSERM U1063, Oxidative Stress and Metabolic Pathologies, Angers University, France; Centre Hospitalo-Universitaire d'Angers, Angers, France
| | - Séverine Dubois
- INSERM U1063, Oxidative Stress and Metabolic Pathologies, Angers University, France; Centre Hospitalo-Universitaire d'Angers, Angers, France
| | - Gilles Simard
- INSERM U1063, Oxidative Stress and Metabolic Pathologies, Angers University, France; Centre Hospitalo-Universitaire d'Angers, Angers, France
| | - Jérôme Boursier
- Centre Hospitalo-Universitaire d'Angers, Angers, France; HIFIH, EA3859, Université d'Angers, Angers, France
| | - Olivier Hue
- Adaptation to Tropical Climate and Exercise Laboratory, EA3596, University of the French West Indies, Pointe-à-Pitre, Guadeloupe, France
| | - M Carmen Martinez
- INSERM U1063, Oxidative Stress and Metabolic Pathologies, Angers University, France
| | | | - Soazig Le Lay
- INSERM U1063, Oxidative Stress and Metabolic Pathologies, Angers University, France.
| |
Collapse
|
22
|
Trzepizur W, Boursier J, Le Vaillant M, Ducluzeau PH, Dubois S, Henni S, Abraham P, Aubé C, Calès P, Gagnadoux F. Increased liver stiffness in patients with severe sleep apnoea and metabolic comorbidities. Eur Respir J 2018; 51:13993003.00601-2018. [PMID: 29880653 DOI: 10.1183/13993003.00601-2018] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2018] [Accepted: 05/01/2018] [Indexed: 02/06/2023]
Abstract
The goal of this study was to assess the relationship between the severity of obstructive sleep apnoea (OSA) and liver stiffness measurement (LSM), one of the most accurate noninvasive screening tools for liver fibrosis in nonalcoholic fatty liver disease.The study included 147 patients with at least one criterion for the metabolic syndrome, assessed by polysomnography for suspected OSA. LSM was performed using transient elastography (FibroScan). Significant liver disease and advanced liver fibrosis were defined as LSM ≥7.3 and ≥9.6 kPa, respectively.23 patients were excluded because of unreliable LSM. Among 124 patients, 34 (27.4%) had mild OSA, 38 (30.6%) had moderate OSA and 52 (42.0%) had severe OSA. LSM values were 7.3- <9.6 kPa in 18 (14.5%) patients and ≥9.6 kPa in 15 (12.1%) patients. A dose-response relationship was observed between OSA severity and LSM values (p=0.004). After adjustment for age, sex, metabolic syndrome and insulin resistance, severe OSA was associated with an increased risk of LSM ≥7.3 kPa (OR 7.17, 95% CI 2.51-20.50) and LSM ≥9.6 kPa (OR 4.73, 95% CI 1.25-17.88).In patients with metabolic comorbidities, severe OSA is independently associated with increased liver stiffness, which may predispose to a higher risk of significant liver disease and poorer prognosis.
Collapse
Affiliation(s)
- Wojciech Trzepizur
- Dépt de Pneumologie, Centre Hospitalier Universitaire, Angers, France.,INSERM UMR 1063, Université d'Angers, Angers, France
| | - Jérôme Boursier
- Dépt d'Hépato-Gastroentérologie, Centre Hospitalier Universitaire, Angers, France.,Laboratoire HIFIH, EA3859, Université d'Angers, Angers, France
| | - Marc Le Vaillant
- Institut de Recherche en Santé Respiratoire des Pays de la Loire, Beaucouzé, France
| | - Pierre-Henri Ducluzeau
- Unité d'Endocrinologie-Diabétologie-Nutrition, Pole de Médecine, Centre Hospitalier Universitaire, Tours, France
| | - Séverine Dubois
- INSERM UMR 1063, Université d'Angers, Angers, France.,Dépt d'Endocrinologie, Diabétologie et Nutrition, Centre Hospitalier Universitaire, Angers, France
| | - Samir Henni
- Dépt de Médecine du Sport et Explorations Fonctionnelles Vasculaires, Centre Hospitalier Universitaire, Angers, France.,Institut MITOVASC, UMR CNRS 6015, INSERM 1083, Université d'Angers, Angers, France
| | - Pierre Abraham
- Dépt de Médecine du Sport et Explorations Fonctionnelles Vasculaires, Centre Hospitalier Universitaire, Angers, France.,Institut MITOVASC, UMR CNRS 6015, INSERM 1083, Université d'Angers, Angers, France
| | - Christophe Aubé
- Laboratoire HIFIH, EA3859, Université d'Angers, Angers, France.,Dépt de Radiologie, Centre Hospitalier Universitaire, Angers, France
| | - Paul Calès
- Dépt d'Hépato-Gastroentérologie, Centre Hospitalier Universitaire, Angers, France.,Laboratoire HIFIH, EA3859, Université d'Angers, Angers, France
| | - Frédéric Gagnadoux
- Dépt de Pneumologie, Centre Hospitalier Universitaire, Angers, France.,INSERM UMR 1063, Université d'Angers, Angers, France
| | | |
Collapse
|
23
|
Chabrol B, Jacquin P, Francois L, Broué P, Dobbelaere D, Douillard C, Dubois S, Feillet F, Perrier A, Fouilhoux A, Labarthe F, Lamireau D, Mazodier K, Maillot F, Mochel F, Schiff M, Belmatoug N. Transition from pediatric to adult care in adolescents with hereditary metabolic diseases: Specific guidelines from the French network for rare inherited metabolic diseases (G2M). Arch Pediatr 2018; 25:S0929-693X(18)30115-5. [PMID: 29914755 DOI: 10.1016/j.arcped.2018.05.009] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2018] [Accepted: 05/20/2018] [Indexed: 11/15/2022]
Abstract
Inherited metabolic diseases (IMD) form a heterogeneous group of genetic disorders that surface primarily during childhood and result in significant morbidity and mortality. A prevalence of 1 in 2500-5000 live births is often reported. The transfer of adolescents from pediatric care to adult health facilities is often difficult for patients and their families and can lead to a breakdown in medical follow-up and therefore serious complications. Existing recommendations for the successful transition of patients with chronic disorders do not specifically address patients with IMDs associated with dietary treatment. Here, the French network for rare inherited metabolic diseases (G2M) presents its reflections and recommendations for a successful transition. Preparations for the transfer must be made well in advance. The transfer must aim for adolescents gaining autonomy by making them responsible and providing them with the knowledge that will enable them to manage their care themselves, know how to react appropriately if there is any change in their condition, and move comfortably within the adult healthcare system. This requires the active participation of the patient, his or her family, and pediatric and adult care teams. It involves multidisciplinary management plus the production and maintenance of an educational therapy program. Finally, the identification of physicians and dietitians trained in IMDs, relevant subspecialists, and even expert patients could improve the continuum of complete and appropriate care for these patients within adult medicine.
Collapse
Affiliation(s)
- B Chabrol
- Hôpital Timone enfants, 264, rue St-Pierre, 13385 Marseille, France.
| | - P Jacquin
- Hôpital Robert-Debré, 48, boulevard Sérurier, 75019 Paris, France
| | - L Francois
- Hôpital Robert-Debré, 48, boulevard Sérurier, 75019 Paris, France
| | - P Broué
- Hôpital des Enfants, 330, avenue de Grande-Bretagne, 31059 Toulouse cedex, France
| | - D Dobbelaere
- Hôpital Jeanne-de-Flandres, CHRU de Lille, avenue Eugène-Avinée, 59037 Lille cedex, France; Hôpital Claude-Huriez, CHRU de Lille, rue Michel-Polonovski, 59000 Lille, France
| | - C Douillard
- Hôpital Jeanne-de-Flandres, CHRU de Lille, avenue Eugène-Avinée, 59037 Lille cedex, France; Hôpital Claude-Huriez, CHRU de Lille, rue Michel-Polonovski, 59000 Lille, France
| | - S Dubois
- Hôpital Necker-Enfants Malades, 149, rue de Sèvres, 75015 Paris, France
| | - F Feillet
- Hopitaux de Brabois, CHU de Nancy, allée du Morvan, 54511 Vandoeuvre-les Nancy, France
| | - A Perrier
- Hôpital femme-mère-enfants, 59, boulevard Pinel, 69677 Bron, France
| | - A Fouilhoux
- Hôpital Clocheville, CHRU de Tours, 49, boulevard Béranger, 37000 Tours, France
| | - F Labarthe
- Hôpital Clocheville, CHRU de Tours, 49, boulevard Béranger, 37000 Tours, France
| | - D Lamireau
- CHU Bordeaux-Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France
| | - K Mazodier
- Hôpital Timone enfants, 264, rue St-Pierre, 13385 Marseille, France
| | - F Maillot
- Hôpital Clocheville, CHRU de Tours, 49, boulevard Béranger, 37000 Tours, France
| | - F Mochel
- Hôpital Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France
| | - M Schiff
- Hôpital Robert-Debré, 48, boulevard Sérurier, 75019 Paris, France
| | - N Belmatoug
- Hôpital Beaujon, 100, boulevard du Général-Leclerc, 92110 Clichy, France
| |
Collapse
|
24
|
Perdomo L, Vergori L, Duluc L, Chwastyniak M, Laudette M, Vidal-Gomez X, Soleti R, Pinet F, Lezoualc’h F, Dubois S, Henni S, Boursier J, Gagnadoux F, Andriantsitohaina R, Martinez M. Critical role of Rap1 in triggering the effects of microparticles from metabolic syndrome patients on vascular smooth muscle cell functions. Archives of Cardiovascular Diseases Supplements 2018. [DOI: 10.1016/j.acvdsp.2018.02.165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
25
|
Daly A, Pinto A, Evans S, Almeida M, Assoun M, Belanger-Quintana A, Bernabei S, Bollhalder S, Cassiman D, Champion H, Chan H, Dalmau J, de Boer F, de Laet C, de Meyer A, Desloovere A, Dianin A, Dixon M, Dokoupil K, Dubois S, Eyskens F, Faria A, Fasan I, Favre E, Feillet F, Fekete A, Gallo G, Gingell C, Gribben J, Kaalund Hansen K, Ter Horst N, Jankowski C, Janssen-Regelink R, Jones I, Jouault C, Kahrs G, Kok I, Kowalik A, Laguerre C, Le Verge S, Lilje R, Maddalon C, Mayr D, Meyer U, Micciche A, Och U, Robert M, Rocha J, Rogozinski H, Rohde C, Ross K, Saruggia I, Schlune A, Singleton K, Sjoqvist E, Skeath R, Stolen L, Terry A, Timmer C, Tomlinson L, Tooke A, Vande Kerckhove K, van Dam E, van den Hurk T, van der Ploeg L, van Driessche M, van Rijn M, van Wegberg A, Vasconcelos C, Vestergaard H, Vitoria I, Webster D, White F, White L, Zweers H, MacDonald A. Dietary practices in propionic acidemia: A European survey. Mol Genet Metab Rep 2017; 13:83-89. [PMID: 29021961 PMCID: PMC5633157 DOI: 10.1016/j.ymgmr.2017.09.002] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2017] [Accepted: 09/21/2017] [Indexed: 12/02/2022] Open
Abstract
Background The definitive dietary management of propionic acidaemia (PA) is unknown although natural protein restriction with adequate energy provision is of key importance. Aim To describe European dietary practices in the management of patients with PA prior to the publication of the European PA guidelines. Methods This was a cross-sectional survey consisting of 27 questions about the dietary practices in PA patients circulated to European IMD dietitians and health professionals in 2014. Results Information on protein restricted diets of 186 PA patients from 47 centres, representing 14 European countries was collected. Total protein intake [PA precursor-free L-amino acid supplements (PFAA) and natural protein] met WHO/FAO/UNU (2007) safe protein requirements for age in 36 centres (77%). PFAA were used to supplement natural protein intake in 81% (n = 38) of centres, providing a median of 44% (14–83%) of total protein requirement. Seventy-four per cent of patients were prescribed natural protein intakes below WHO/FAO/UNU (2007) safe levels in one or more of the following age groups: 0–6 m, 7–12 m, 1–10 y, 11–16 y and > 16 y. Sixty-three per cent (n = 117) of patients were tube fed (74% gastrostomy), but only 22% received nocturnal feeds. Conclusions There was high use of PFAA with intakes of natural protein commonly below WHO/FAO/UNU (2007) safe levels. Optimal dietary management can only be determined by longitudinal, multi-centre, prospective case controlled studies. The metabolic instability of PA and small patient cohorts in each centre ensure that this is a challenging undertaking.
Collapse
Affiliation(s)
- A. Daly
- Birmingham Women's and Children's Hospital, Birmingham, UK
| | - A. Pinto
- Birmingham Women's and Children's Hospital, Birmingham, UK
| | - S. Evans
- Birmingham Women's and Children's Hospital, Birmingham, UK
| | - M.F. Almeida
- Centro de Genética Médica, Centro Hospitalar do Porto - CHP, Porto, Portugal
- Unit for Multidisciplinary Research in Biomedicine, Abel Salazar Institute of Biomedical Sciences, University of Porto-UMIB/ICBAS/UP, Porto, Portugal
- Centro de Referência na área de Doenças Hereditárias do Metabolismo, Centro Hospitalar do Porto - CHP, Porto, Portugal
| | - M. Assoun
- Centre de référence des maladies héréditaires du métabolisme, Hôpital Necker Enfants Malades, Paris, France
| | - A. Belanger-Quintana
- Unidad de Enfermedades Metabolicas, Servicio de Pediatria, Hospital Ramon y Cajal Madrid, Spain
| | - S.M. Bernabei
- Children Hospital Bambino Gesù, Division of Artificial Nutrition, Rome, Italy
| | | | - D. Cassiman
- Metabolic Center, University Hospitals Leuven and KU Leuven, Belgium
| | | | - H. Chan
- Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - J. Dalmau
- Unit of Nutrition and Metabolopathies, Hospital La Fe, Valencia, Spain
| | - F. de Boer
- University of Groningen, University Medical Center Groningen, Netherlands
| | - C. de Laet
- Hôpital Universitaire des Enfants, Reine Fabiola, Bruxelles, Belgium
| | - A. de Meyer
- Center of Metabolic Diseases, University Hospital, Antwerp, Belgium
| | | | - A. Dianin
- Department of Pediatrics, Regional Centre for Newborn Screening, Diagnosis and Treatment of Inherited Metabolic Diseases and Congenital Endocrine Diseases, University Hospital of Verona, Italy
| | - M. Dixon
- Great Ormond Street Hospital for Children NHS FoundationTrust, London, UK
| | - K. Dokoupil
- Dr. von Hauner Children's Hospital, Munich, Germany
| | - S. Dubois
- Centre de référence des maladies héréditaires du métabolisme, Hôpital Necker Enfants Malades, Paris, France
| | - F. Eyskens
- Center of Metabolic Diseases, University Hospital, Antwerp, Belgium
| | - A. Faria
- Hospital Pediátrico, Centro Hospitalar e Universitário de Coimbra, EPE, Portugal
| | - I. Fasan
- Division of Inherited Metabolic Diseases, Department of Pediatrics, University Hospital of Padova, Italy
| | - E. Favre
- Reference center for Inborn Errors of Metabolism, Department of Pediatrics, Children's University Hospital, Nancy, France
| | - F. Feillet
- Reference center for Inborn Errors of Metabolism, Department of Pediatrics, Children's University Hospital, Nancy, France
| | | | - G. Gallo
- Children Hospital Bambino Gesù, Division of Artificial Nutrition, Rome, Italy
| | | | - J. Gribben
- Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - K. Kaalund Hansen
- Charles Dent Metabolic Unit National Hospital for Neurology and Surgery, London, UK
| | | | - C. Jankowski
- Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, UK
| | | | - I. Jones
- Center of Metabolic Diseases, University Hospital, Antwerp, Belgium
| | | | - G.E. Kahrs
- Haukeland University Hospital, Bergen, Norway
| | - I.L. Kok
- Wilhelmina Children's Hospital, University Medical Centre Utrecht, Netherlands
| | - A. Kowalik
- Institute of Mother & Child, Warsaw, Poland
| | - C. Laguerre
- Centre de Compétence de L'Hôpital des Enfants de Toulouse, France
| | - S. Le Verge
- Centre de référence des maladies héréditaires du métabolisme, Hôpital Necker Enfants Malades, Paris, France
| | - R. Lilje
- Oslo University Hospital, Norway
| | - C. Maddalon
- University Children's Hospital Zurich, Switzerland
| | - D. Mayr
- Ernährungsmedizinische Beratung, Universitätsklinik für Kinder- und Jugendheilkunde, Salzburg, Austria
| | - U. Meyer
- Clinic of Paediatric Kidney, Liver- and Metabolic Diseases, Medical School Hannover, Germany
| | - A. Micciche
- Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - U. Och
- University Children's Hospital, Munster, Germany
| | - M. Robert
- Hôpital Universitaire des Enfants, Reine Fabiola, Bruxelles, Belgium
| | - J.C. Rocha
- Centro de Genética Médica, Centro Hospitalar do Porto - CHP, Porto, Portugal
- Centro de Referência na área de Doenças Hereditárias do Metabolismo, Centro Hospitalar do Porto - CHP, Porto, Portugal
- Faculdade de Ciências da Saúde, Universidade Fernando Pessoa, Portugal
- Centre for Health Technology and Services Research (CINTESIS), Portugal
| | | | - C. Rohde
- Hospital of Children's & Adolescents, University of Leipzig, Germany
| | - K. Ross
- Royal Aberdeen Children's Hospital, Scotland
| | - I. Saruggia
- Centre de Reference des Maladies Héréditaires du Métabolisme du Pr. B. Chabrol CHU Timone Enfant, Marseille, France
| | - A. Schlune
- Department of General Pediatrics, Neonatology and Pediatric Cardiology, University Children's Hospital, Heinrich Heine University, Moorenstr. 5, 40225 Düsseldorf, Germany
| | | | - E. Sjoqvist
- Children's Hospital, University Hospital, Lund, Sweden
| | - R. Skeath
- Great Ormond Street Hospital for Children NHS FoundationTrust, London, UK
| | | | - A. Terry
- Alder Hey Children's Hospital NHS Foundation Trust Liverpool, UK
| | - C. Timmer
- Academisch Medisch Centrum, Amsterdam, Netherlands
| | - L. Tomlinson
- University Hospitals Birmingham NHS Foundation Trust, UK
| | - A. Tooke
- Nottingham University Hospitals, UK
| | | | - E. van Dam
- University of Groningen, University Medical Center Groningen, Netherlands
| | - T. van den Hurk
- Wilhelmina Children's Hospital, University Medical Centre Utrecht, Netherlands
| | | | | | - M. van Rijn
- University of Groningen, University Medical Center Groningen, Netherlands
| | | | - C. Vasconcelos
- Centro Hospitalar São João - Unidade de Doenças Metabólicas, Porto, Portugal
| | | | - I. Vitoria
- Unit of Nutrition and Metabolopathies, Hospital La Fe, Valencia, Spain
| | - D. Webster
- Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, UK
| | - F.J. White
- Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK
| | - L. White
- Sheffield Children's Hospital, UK
| | - H. Zweers
- Radboud University Medical Center Nijmegen, Netherlands
| | - A. MacDonald
- Birmingham Women's and Children's Hospital, Birmingham, UK
- Corresponding author at: Dietetic Department, Birmingham Children's Hospital, Steelhouse Lane, Birmingham B4 6NH, UK.Dietetic DepartmentBirmingham Children's HospitalSteelhouse LaneBirminghamB4 6NHUK
| |
Collapse
|
26
|
Dubois S, Chassaing E, Duvail JL, Piraux L, Waals MG. Preparation and characterization of electrodeposited Fe and Fe/Cu nanowires. ACTA ACUST UNITED AC 2017. [DOI: 10.1051/jcp:1999213] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
27
|
Jardin F, Mareschal S, Pham-Ledard A, Viailly P, Carlotti M, Dubois S, Bertrand P, Maingonnat C, Bohers E, Ruminy P, Tournier I, Courville P, Duval A, Andrieu E, Verneuil L, Fontanillles M, Vergier B, Tilly H, Joly P, Frebourg T, Beylot-Barry M, Merlio J. THE LANDSCAPE OF SOMATIC MUTATIONS OF PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA, LEG-TYPE. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_97] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- F. Jardin
- Hematology; Henri Becquerel Center; Rouen France
| | - S. Mareschal
- Team Genetics and Biomarkers in Lymphoma and Solid Tumors, INSERM U1245; Rouen France
| | - A. Pham-Ledard
- Inserm U1053, Team “Oncogenesis of Cutaneous Lymphoma”, CHU Bordeaux; Bordeaux France
| | - P. Viailly
- Team Genetics and Biomarkers in Lymphoma and Solid Tumors, INSERM U1245; Rouen France
| | - M. Carlotti
- Inserm U1053, Team “Oncogenesis of Cutaneous Lymphoma”, CHU Bordeaux; Bordeaux France
| | - S. Dubois
- Team Genetics and Biomarkers in Lymphoma and Solid Tumors, INSERM U1245; Rouen France
| | - P. Bertrand
- Team Genetics and Biomarkers in Lymphoma and Solid Tumors, INSERM U1245; Rouen France
| | - C. Maingonnat
- Team Genetics and Biomarkers in Lymphoma and Solid Tumors, INSERM U1245; Rouen France
| | - E. Bohers
- Team Genetics and Biomarkers in Lymphoma and Solid Tumors, INSERM U1245; Rouen France
| | - P. Ruminy
- Team Genetics and Biomarkers in Lymphoma and Solid Tumors, INSERM U1245; Rouen France
| | - I. Tournier
- Department of Genetics, Normandie Univ, UNIROUEN; Inserm U1245 and Rouen University Hospital; Rouen France
| | - P. Courville
- Departments of Dermatology and Pathology; Rouen University Hospital; Rouen France
| | - A. Duval
- Departments of Dermatology and Pathology; Rouen University Hospital; Rouen France
| | - E. Andrieu
- Departments of Dermatology and Pathology; Rouen University Hospital; Rouen France
| | - L. Verneuil
- Departments of Dermatology and Pathology, Caen CHU; Caen France
| | - M. Fontanillles
- Team Genetics and Biomarkers in Lymphoma and Solid Tumors, INSERM U1245; Rouen France
| | - B. Vergier
- Inserm U1053, Team “Oncogenesis of Cutaneous Lymphoma”, CHU Bordeaux; Bordeaux France
| | - H. Tilly
- Team Genetics and Biomarkers in Lymphoma and Solid Tumors, INSERM U1245; Rouen France
| | - P. Joly
- Departments of Dermatology and Pathology; Rouen University Hospital; Rouen France
| | - T. Frebourg
- Department of Genetics, Normandie Univ, UNIROUEN; Inserm U1245 and Rouen University Hospital; Rouen France
| | - M. Beylot-Barry
- Inserm U1053, Team “Oncogenesis of Cutaneous Lymphoma”, CHU Bordeaux; Bordeaux France
| | - J. Merlio
- Inserm U1053, Team “Oncogenesis of Cutaneous Lymphoma”, CHU Bordeaux; Bordeaux France
| |
Collapse
|
28
|
Malloci M, Esnault M, Dubois S, Boursier J, Gagnadoux F, Andriantsitohaina R, Simard G, Martinez M. Changes of mitochondrial dynamic evoked by circulating exosomes are associated to endothelial dysfunction in metabolic syndrome. Archives of Cardiovascular Diseases Supplements 2017. [DOI: 10.1016/s1878-6480(17)30463-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
29
|
Bironneau V, Goupil F, Ducluzeau PH, Le Vaillant M, Abraham P, Henni S, Dubois S, Paris A, Priou P, Meslier N, Sanguin C, Trzépizur W, Andriantsitohaina R, Martinez MC, Gagnadoux F. Association between obstructive sleep apnea severity and endothelial dysfunction in patients with type 2 diabetes. Cardiovasc Diabetol 2017; 16:39. [PMID: 28327146 PMCID: PMC5361793 DOI: 10.1186/s12933-017-0521-y] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/04/2017] [Accepted: 03/15/2017] [Indexed: 12/11/2022] Open
Abstract
Background Obstructive sleep apnea (OSA) and type 2 diabetes (T2D) are associated with endothelial dysfunction a main predictor of late cardiovascular (CV) events. Despite the high prevalence of OSA in patients with T2D, the impact of OSA severity on endothelial function has not been clearly elucidated. The aim of this cross-sectional study was to determine whether increasing OSA severity is associated with poorer endothelial function in patients with T2D. Methods 140 patients with T2D and no overt CV disease underwent polysomnography, peripheral arterial tonometry, clinic blood pressure (BP) measurement, biological assessment for CV risk factors, daytime sleepiness and health related quality of life (HRQL) questionnaires. The following commonly used cut-offs for apnea-hypopnea index (AHI) were used to define 3 categories of disease severity: AHI < 15 (no OSA or mild OSA), 15 ≤ AHI < 30 (moderate OSA), and AHI ≥ 30 (severe OSA). The primary outcome was the reactive hyperemia index (RHI), a validated assessment of endothelial function. Results 21.4% of patients had moderate OSA and 47.6% had severe OSA. Increasing OSA severity and nocturnal hypoxemia were not associated with a significant decrease in RHI. Endothelial dysfunction (RHI < 1.67) was found in 47.1, 44.4 and 39.2% of patients with no OSA or mild OSA, moderate OSA and severe OSA, respectively (p = 0.76). After adjustment for confounders including body mass index, increasing OSA severity was associated with higher systolic BP (p = 0.03), lower circulating levels of adiponectin (p = 0.0009), higher levels of sP-selectin (p = 0.03), lower scores in 3 domains of HRQL including energy/vitality (p = 0.02), role functioning (p = 0.01), and social functioning (p = 0.04). Conclusions Moderate to severe OSA is very common but has no impact on digital micro-vascular endothelial function in patients with T2D.
Collapse
Affiliation(s)
| | | | - Pierre Henri Ducluzeau
- Unité d'Endocrinologie-Diabétologie-Nutrition, Pole de Médecine, CHRU de Tours, Tours, France
| | - Marc Le Vaillant
- Centre de Recherche Médecine, Sciences, Santé, Santé mentale, Société, CNRS UMR 8211, INSERM UMR U988-EHESS, Villejuif, France
| | - Pierre Abraham
- Département de Médecine du Sport et Explorations Fonctionnelles Vasculaires, Université Bretagne Loire, CHU d'Angers, Angers, France
| | - Samir Henni
- Département de Médecine du Sport et Explorations Fonctionnelles Vasculaires, Université Bretagne Loire, CHU d'Angers, Angers, France
| | - Séverine Dubois
- Département d'Endocrinologie, Diabétologie, Nutrition, Université Bretagne Loire, CHU d'Angers, Angers, France
| | - Audrey Paris
- Service de Pneumologie, Centre Hospitalier, Le Mans, France
| | - Pascaline Priou
- Université Bretagne Loire, INSERM UMR 1063, Angers, France.,Département de Pneumologie, Université Bretagne Loire, CHU d'Angers, 4 Rue Larrey, 49100, Angers, France
| | - Nicole Meslier
- Université Bretagne Loire, INSERM UMR 1063, Angers, France.,Département de Pneumologie, Université Bretagne Loire, CHU d'Angers, 4 Rue Larrey, 49100, Angers, France
| | - Claire Sanguin
- Service d'Endocrinologie, Diabétologie, Centre Hospitalier, Le Mans, France
| | - Wojciech Trzépizur
- Université Bretagne Loire, INSERM UMR 1063, Angers, France.,Département de Pneumologie, Université Bretagne Loire, CHU d'Angers, 4 Rue Larrey, 49100, Angers, France
| | | | | | - Frédéric Gagnadoux
- Université Bretagne Loire, INSERM UMR 1063, Angers, France. .,Département de Pneumologie, Université Bretagne Loire, CHU d'Angers, 4 Rue Larrey, 49100, Angers, France.
| |
Collapse
|
30
|
Marche P, Dubois S, Abraham P, Parot-Schinkel E, Gascoin L, Humeau-Heurtier A, Ducluzeau PH, Mahe G. Neurovascular microcirculatory vasodilation mediated by C-fibers and Transient receptor potential vanilloid-type-1 channels (TRPV 1) is impaired in type 1 diabetes. Sci Rep 2017; 7:44322. [PMID: 28287157 PMCID: PMC5347083 DOI: 10.1038/srep44322] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2016] [Accepted: 02/06/2017] [Indexed: 01/20/2023] Open
Abstract
Microvascular dysfunction may have an early onset in type 1 diabetes (T1D) and can precede major complications. Our objectives were to assess the endothelial-dependent (acetylcholine, ACh; and post-occlusive hyperemia, PORH), non-endothelial-dependent (sodium nitroprusside, SNP) and neurovascular-dependent (local heating, LH and current induced vasodilation, CIV) microcirculatory vasodilation in T1D patients compared with matched control subjects using a laser speckle contrast imager. Seventeen T1D patients - matched with 17 subjects according to age, gender, Body-Mass-Index, and smoking status - underwent macro- and microvascular investigations. The LH early peak assessed the transient receptor potential vanilloid type 1 channels (TRPV1) mediated vasodilation, whereas the plateau assessed the Nitirc-Oxyde (NO) and endothelium-derived hyperpolarizing factor (EDHF) pathways. PORH explored sensory nerves and (EDHF), while CIV assessed sensory nerves (C-fibers) and prostaglandin-mediated vasodilation. Using neurological investigations, we observed that C-fiber and A-delta fiber functions in T1D patients were similar to control subjects. PORH, CIV, LH peak and plateau vasodilations were significantly decreased in T1D patients compared to controls, whereas there was no difference between the two groups for ACh and SNP vasodilations. Neurovascular microcirculatory vasodilations (C-fibers and TRPV 1-mediated vasodilations) are impaired in TD1 patients whereas no abnormalities were found using clinical neurological investigations. Clinicaltrials: No. NCT02538120.
Collapse
Affiliation(s)
- P Marche
- Endocrinology Department, University Hospital of Angers, Angers, France
| | - S Dubois
- Endocrinology Department, University Hospital of Angers, Angers, France
| | - P Abraham
- Laboratory of Vascular Investigations, University Hospital of Angers, UMR CNRS6214/INSERM1083, LUNAM Université, Angers, France
| | - E Parot-Schinkel
- Methodology and Biostatistics Unit, University Hospital of Angers, Angers, France
| | - L Gascoin
- Laboratory of Vascular Investigations, University Hospital of Angers, UMR CNRS6214/INSERM1083, LUNAM Université, Angers, France
| | - A Humeau-Heurtier
- University of Angers, LARIS - Laboratoire Angevin de Recherche en Ingénierie des Systèmes, Angers, France
| | - P H Ducluzeau
- Endocrinology Department, University Hospital of Tours, Tours, France
| | - G Mahe
- INSERM Clinical Investigation Center (CIC 14 14), Rennes, France, Université de Rennes 1 and LUNAM University, Inserm 1083/CNRS 6214, Faculty of Medicine, Angers, France
| |
Collapse
|
31
|
Pinto A, Daly A, Evans S, Almeida MF, Assoun M, Belanger-Quintana A, Bernabei S, Bollhalder S, Cassiman D, Champion H, Chan H, Dalmau J, de Boer F, de Laet C, de Meyer A, Desloovere A, Dianin A, Dixon M, Dokoupil K, Dubois S, Eyskens F, Faria A, Fasan I, Favre E, Feillet F, Fekete A, Gallo G, Gingell C, Gribben J, Kaalund-Hansen K, Horst N, Jankowski C, Janssen-Regelink R, Jones I, Jouault C, Kahrs GE, Kok IL, Kowalik A, Laguerre C, Le Verge S, Lilje R, Maddalon C, Mayr D, Meyer U, Micciche A, Robert M, Rocha JC, Rogozinski H, Rohde C, Ross K, Saruggia I, Schlune A, Singleton K, Sjoqvist E, Stolen LH, Terry A, Timmer C, Tomlinson L, Tooke A, Vande Kerckhove K, van Dam E, van den Hurk T, van der Ploeg L, van Driessche M, van Rijn M, van Teeffelen-Heithoff A, van Wegberg A, Vasconcelos C, Vestergaard H, Vitoria I, Webster D, White FJ, White L, Zweers H, MacDonald A. Dietary practices in isovaleric acidemia: A European survey. Mol Genet Metab Rep 2017; 12:16-22. [PMID: 28275552 PMCID: PMC5328917 DOI: 10.1016/j.ymgmr.2017.02.001] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2017] [Accepted: 02/14/2017] [Indexed: 12/21/2022] Open
Abstract
Background In Europe, dietary management of isovaleric acidemia (IVA) may vary widely. There is limited collective information about dietetic management. Aim To describe European practice regarding the dietary management of IVA, prior to the availability of the E-IMD IVA guidelines (E-IMD 2014). Methods A cross-sectional questionnaire was sent to all European dietitians who were either members of the Society for the Study of Inborn Errors of Metabolism Dietitians Group (SSIEM-DG) or whom had responded to previous questionnaires on dietetic practice (n = 53). The questionnaire comprised 27 questions about the dietary management of IVA. Results Information on 140 patients with IVA from 39 centres was reported. 133 patients (38 centres) were given a protein restricted diet. Leucine-free amino acid supplements (LFAA) were routinely used to supplement protein intake in 58% of centres. The median total protein intake prescribed achieved the WHO/FAO/UNU [2007] safe levels of protein intake in all age groups. Centres that prescribed LFAA had lower natural protein intakes in most age groups except 1 to 10 y. In contrast, when centres were not using LFAA, the median natural protein intake met WHO/FAO/UNU [2007] safe levels of protein intake in all age groups. Enteral tube feeding was rarely prescribed. Conclusions This survey demonstrates wide differences in dietary practice in the management of IVA across European centres. It provides unique dietary data collectively representing European practices in IVA which can be used as a foundation to compare dietary management changes as a consequence of the first E-IMD IVA guidelines availability.
Collapse
Affiliation(s)
- A Pinto
- Birmingham Children's Hospital, Birmingham, UK
| | - A Daly
- Birmingham Children's Hospital, Birmingham, UK
| | - S Evans
- Birmingham Children's Hospital, Birmingham, UK
| | - M F Almeida
- Centro de Genética Médica, Centro Hospitalar do Porto - CHP, Porto, Portugal; Unit for Multidisciplinary Research in Biomedicine, Abel Salazar Institute of Biomedical Sciences, University of Porto-UMIB/ICBAS/UP, Porto, Portugal
| | - M Assoun
- Centre de référence des maladies héréditaires du métabolisme, hôpital Necker enfants Malades, Paris
| | - A Belanger-Quintana
- Unidad de Enfermedades Metabolicas, Servicio de Pediatria, Hospital Ramon y Cajal Madrid, Spain
| | - S Bernabei
- Children's Hospital Bambino Gesù, Division of Metabolism, Rome, Italy
| | | | - D Cassiman
- Metabolic Center, University Hospitals Leuven and KU Leuven, Belgium
| | | | - H Chan
- Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - J Dalmau
- Unit of Nutrition and Metabolopathies, Hospital La Fe, Valencia, Spain
| | - F de Boer
- University of Groningen, University Medical Center Groningen, Netherlands
| | - C de Laet
- Hôpital Universitaire des Enfants, Reine Fabiola, Bruxelles, Belgium
| | - A de Meyer
- Center of Metabolic Diseases, University Hospital, Antwerp, Belgium
| | | | - A Dianin
- Pediatric Department, University Hospital of Borgo Roma Verona, Italy
| | - M Dixon
- Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
| | - K Dokoupil
- Dr. von Hauner Children's Hospital, Munich, Germany
| | - S Dubois
- Centre de référence des maladies héréditaires du métabolisme, hôpital Necker enfants Malades, Paris
| | - F Eyskens
- Center of Metabolic Diseases, University Hospital, Antwerp, Belgium
| | - A Faria
- Hospital Pediatrico, Centro Hospitalar e Universitário de Coimbra, EPE, Portugal
| | - I Fasan
- Division of Inherited Metabolic Diseases, Department of Pediatrics, University Hospital of Padova, Italy
| | - E Favre
- Reference center for Inborn Errors of Metabolism, Department of Pediatrics, Children's University Hospital, Nancy, France
| | - F Feillet
- Reference center for Inborn Errors of Metabolism, Department of Pediatrics, Children's University Hospital, Nancy, France
| | - A Fekete
- Metabolic Centre of Vienna, Austria
| | - G Gallo
- Children's Hospital Bambino Gesù, Division of Metabolism, Rome, Italy
| | | | - J Gribben
- Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - K Kaalund-Hansen
- Charles Dent Metabolic Unit National Hospital for Neurology and Surgery, London, UK
| | - N Horst
- Emma Children's Hospital, AMC Amsterdam, Netherlands
| | - C Jankowski
- Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, UK
| | | | - I Jones
- Center of Metabolic Diseases, University Hospital, Antwerp, Belgium
| | | | - G E Kahrs
- Haukeland University Hospital, Bergen, Norway
| | - I L Kok
- Wilhelmina Children's Hospital, University Medical Centre Utrecht, Netherlands
| | - A Kowalik
- Institute of Mother & Child, Warsaw, Poland
| | - C Laguerre
- Centre de Compétence de L'Hôpital des Enfants de Toulouse, France
| | - S Le Verge
- Centre de référence des maladies héréditaires du métabolisme, hôpital Necker enfants Malades, Paris
| | - R Lilje
- Oslo University Hospital, Norway
| | - C Maddalon
- University Children's Hospital Zurich, Switzerland
| | - D Mayr
- Ernährungsmedizinische Beratung, Universitätsklinik für Kinder- und Jugendheilkunde, Salzburg, Austria
| | - U Meyer
- Clinic of Paediatric Kidney, Liver and Metabolic Diseases, Medical School Hannover, Germany
| | - A Micciche
- Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - M Robert
- Hôpital Universitaire des Enfants, Reine Fabiola, Bruxelles, Belgium
| | - J C Rocha
- Centro de Genética Médica, Centro Hospitalar do Porto - CHP, Porto, Portugal; Faculdade de Ciências da Saúde, Universidade Fernando Pessoa, Portugal; Centre for Health Technology and Services Research (CINTESIS), Portugal
| | - H Rogozinski
- Bradford Teaching Hospital NHS Foundation Trust, UK
| | - C Rohde
- Hospital of Children's & Adolescents, University of Leipzig, Germany
| | - K Ross
- Royal Aberdeen Children's Hospital, Scotland
| | - I Saruggia
- Centre de Reference des Maladies Héréditaires du Métabolisme du Pr. B. Chabrol CHU Timone Enfant, Marseille, France
| | - A Schlune
- Department of General Pediatrics, Neonatology and Pediatric Cardiology, University Children's Hospital, Heinrich Heine University, Moorenstr. 5, 40225 Düsseldorf, Germany
| | | | - E Sjoqvist
- Children's Hospital, University Hospital, Lund, Sweden
| | | | - A Terry
- Alder Hey Children's Hospital NHS Foundation Trust Liverpool, UK
| | - C Timmer
- Academisch Medisch Centrum, Amsterdam, Netherlands
| | - L Tomlinson
- University Hospitals Birmingham NHS Foundation Trust, UK
| | - A Tooke
- Nottingham University Hospitals, UK
| | - K Vande Kerckhove
- Metabolic Center, University Hospitals Leuven and KU Leuven, Belgium
| | - E van Dam
- University of Groningen, University Medical Center Groningen, Netherlands
| | - T van den Hurk
- Wilhelmina Children's Hospital, University Medical Centre Utrecht, Netherlands
| | - L van der Ploeg
- Maastricht University Medical Centre + (MUMC +), Netherlands
| | | | - M van Rijn
- University of Groningen, University Medical Center Groningen, Netherlands
| | | | - A van Wegberg
- Radboud University Medical Center Nijmegen, The Netherlands
| | - C Vasconcelos
- Centro Hospitalar São João - Unidade de Doenças Metabólicas, Porto, Portugal
| | | | - I Vitoria
- Unit of Nutrition and Metabolopathies, Hospital La Fe, Valencia, Spain
| | - D Webster
- Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, UK
| | - F J White
- Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK
| | - L White
- Sheffield Children's Hospital, UK
| | - H Zweers
- Radboud University Medical Center Nijmegen, The Netherlands
| | - A MacDonald
- Birmingham Children's Hospital, Birmingham, UK
| |
Collapse
|
32
|
Bironneau V, Martinez M, Le Vaillant M, Dubois S, Ducluzeau P, Goupil F, Paris A, Priou P, Meslier N, Sanguin C, Trzepizur W, Andriantsitohaina R, Abraham P, Gagnadoux F. Impact du syndrome d’apnées hypopnées obstructives du sommeil sur la fonction endothéliale chez les patients atteints de diabète de type 2. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
33
|
Safiedeen Z, Rodríguez-Gómez I, Vergori L, Soleti R, Vaithilingam D, Douma I, Agouni A, Leiber D, Dubois S, Simard G, Zibara K, Andriantsitohaina R, Martínez MC. Temporal Cross Talk Between Endoplasmic Reticulum and Mitochondria Regulates Oxidative Stress and Mediates Microparticle-Induced Endothelial Dysfunction. Antioxid Redox Signal 2017; 26:15-27. [PMID: 27392575 DOI: 10.1089/ars.2016.6771] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
AIMS Circulating microparticles (MPs) from metabolic syndrome patients and those generated from apoptotic T cells induce endothelial dysfunction; however, the molecular and cellular mechanism(s) underlying in the effects of MPs remain to be elucidated. RESULTS Here, we show that both types of MPs increased expression of endoplasmic reticulum (ER) stress markers, X-box binding protein 1, p-eukaryotic translation initiation factor 2 α, and CHOP, and nuclear translocation of activating transcription factor 6 on human aortic endothelial cells (HAoECs). MPs decreased in vitro nitric oxide release by HAoECs, whereas in vivo MP injection into mice impaired the endothelium-dependent relaxation induced by acetylcholine. These effects were prevented when ER stress was inhibited, suggesting that ER stress is implicated in the endothelial effects induced by MPs. MPs affected mitochondrial function and evoked sequential increase of cytosolic and mitochondrial reactive oxygen species (ROS). Pharmacological inhibition of ER stress and silencing of neutral sphingomyelinase (SMase) with siRNA abrogated all MP-mediated effects. Neutralization of Fas ligand carried by MPs abolished effects induced by both MP types, whereas neutralization of low-density lipoprotein receptor on endothelial cells prevented T-lymphocyte MP-mediated effects. Innovation and Conclusion: Collectively, endothelial dysfunction triggered by MPs involves temporal cross talk between ER and mitochondria with respect to spatial regulation of ROS via the neutral SMase and interaction of MPs with Fas and/or low-density lipoprotein receptor. These results provide a novel molecular insight into the manner MPs mediate vascular dysfunction and allow identification of potential therapeutic targets to treat vascular complications associated with metabolic syndrome. Antioxid. Redox Signal. 26, 15-27.
Collapse
Affiliation(s)
- Zainab Safiedeen
- 1 INSERM U1063, Stress Oxydant et Pathologies Métaboliques, Institut de Biologie en Santé, Université d'Angers , Angers, France .,2 ER045, Laboratory of Stem Cells, PRASE, DSST, Lebanese University , Beirut, Lebanon
| | - Isabel Rodríguez-Gómez
- 1 INSERM U1063, Stress Oxydant et Pathologies Métaboliques, Institut de Biologie en Santé, Université d'Angers , Angers, France
| | - Luisa Vergori
- 1 INSERM U1063, Stress Oxydant et Pathologies Métaboliques, Institut de Biologie en Santé, Université d'Angers , Angers, France
| | - Raffaella Soleti
- 1 INSERM U1063, Stress Oxydant et Pathologies Métaboliques, Institut de Biologie en Santé, Université d'Angers , Angers, France
| | - Dayannath Vaithilingam
- 1 INSERM U1063, Stress Oxydant et Pathologies Métaboliques, Institut de Biologie en Santé, Université d'Angers , Angers, France
| | - Imene Douma
- 1 INSERM U1063, Stress Oxydant et Pathologies Métaboliques, Institut de Biologie en Santé, Université d'Angers , Angers, France
| | - Abdelali Agouni
- 3 Faculty of Health and Medical Sciences, University of Surrey , Guildford, United Kingdom
| | - Denis Leiber
- 1 INSERM U1063, Stress Oxydant et Pathologies Métaboliques, Institut de Biologie en Santé, Université d'Angers , Angers, France
| | - Séverine Dubois
- 1 INSERM U1063, Stress Oxydant et Pathologies Métaboliques, Institut de Biologie en Santé, Université d'Angers , Angers, France .,4 Centre Hospitalo-Universitaire d'Angers , Angers, France
| | - Gilles Simard
- 1 INSERM U1063, Stress Oxydant et Pathologies Métaboliques, Institut de Biologie en Santé, Université d'Angers , Angers, France .,4 Centre Hospitalo-Universitaire d'Angers , Angers, France
| | - Kazem Zibara
- 2 ER045, Laboratory of Stem Cells, PRASE, DSST, Lebanese University , Beirut, Lebanon .,5 Faculty of Sciences-I, Biology Department, Lebanese University , Beirut, Lebanon
| | - Ramaroson Andriantsitohaina
- 1 INSERM U1063, Stress Oxydant et Pathologies Métaboliques, Institut de Biologie en Santé, Université d'Angers , Angers, France .,4 Centre Hospitalo-Universitaire d'Angers , Angers, France
| | - M Carmen Martínez
- 1 INSERM U1063, Stress Oxydant et Pathologies Métaboliques, Institut de Biologie en Santé, Université d'Angers , Angers, France .,4 Centre Hospitalo-Universitaire d'Angers , Angers, France
| |
Collapse
|
34
|
Dubois S, Barbier A, Thibault M, Atkinson S, Bussières JF. [Selection and optimal sequence of critical elements for medication review: A simulation with hospital pharmacy residents]. Ann Pharm Fr 2016; 75:131-143. [PMID: 27423187 DOI: 10.1016/j.pharma.2016.06.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2016] [Revised: 06/03/2016] [Accepted: 06/14/2016] [Indexed: 12/30/2022]
Abstract
OBJECTIVES The main objective of this study was to compare the responses of pharmacy residents regarding critical steps for medication order review, in the presence or absence of clinical pharmacists on patient care units, to describe the sequence of these steps and to compare them to an optimal sequence. The secondary objectives were to test this sequence in a simulation and to assess the residents' level of agreement on medication order review. METHODS Twenty-two validation steps were selected from guidelines. A simulation on order review was organized in three steps: selecting elements judged to be necessary or not for the order review critical path, then organizing this sequence in chronological order, implementation of this critical path on two simulated practical cases, resident perceptions about order review in their training. RESULTS Forty-one residents participated in the activity. Responses were heterogeneous regarding the elements' sequence and the time required for the review of a simulated case (3-13minutes). A majority of residents considered that their training was insufficient (29/41), that pharmacists validated differently (27/41), and that it was impossible to review the 22 proposed items for each prescription (30/41). CONCLUSIONS This article highlights heterogeneous medication order review practices among pharmacy residents, due to a lack of training in their curriculum according to them. It is essential to acquire medication order review standard both locally and nationally.
Collapse
Affiliation(s)
- S Dubois
- Unité de recherche en pratique pharmaceutique, département de pharmacie, CHU Sainte-Justine, 3175, Côte-Sainte-Catherine, H3T1C5 Montréal, QC, Canada
| | - A Barbier
- Unité de recherche en pratique pharmaceutique, département de pharmacie, CHU Sainte-Justine, 3175, Côte-Sainte-Catherine, H3T1C5 Montréal, QC, Canada
| | - M Thibault
- Unité de recherche en pratique pharmaceutique, département de pharmacie, CHU Sainte-Justine, 3175, Côte-Sainte-Catherine, H3T1C5 Montréal, QC, Canada
| | - S Atkinson
- Unité de recherche en pratique pharmaceutique, département de pharmacie, CHU Sainte-Justine, 3175, Côte-Sainte-Catherine, H3T1C5 Montréal, QC, Canada
| | - J-F Bussières
- Unité de recherche en pratique pharmaceutique, département de pharmacie, CHU Sainte-Justine, 3175, Côte-Sainte-Catherine, H3T1C5 Montréal, QC, Canada; Faculté de pharmacie et des sciences pharmaceutiques, université de Montréal, 6128, succursale Centre-Ville, H3C3J7 Montréal, QC, Canada.
| |
Collapse
|
35
|
Le Reste C, Fiedler A, Dubois S, Dewailly A, Le Du I, Cogulet V. Comment promouvoir le respect des bonnes pratiques de perfusion en allant à la rencontre des soignants ? Annales Pharmaceutiques Françaises 2016; 74:232-43. [DOI: 10.1016/j.pharma.2015.10.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2015] [Revised: 10/14/2015] [Accepted: 10/26/2015] [Indexed: 11/28/2022]
|
36
|
Malloci M, Dubois S, Andriantsitohaina R, Simard G, Martinez C. 0274 : Exosomes from metabolic syndrome patients induce endothelial dysfunction through mitochondrial-generated oxidative stress. Archives of Cardiovascular Diseases Supplements 2016. [DOI: 10.1016/s1878-6480(16)30395-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
37
|
Monseu M, Dubois S, Boursier J, Aubé C, Gagnadoux F, Lefthériotis G, Ducluzeau PH. Osteoprotegerin levels are associated with liver fat and liver markers in dysmetabolic adults. Diabetes Metab 2016; 42:364-367. [PMID: 27016890 DOI: 10.1016/j.diabet.2016.02.004] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/21/2015] [Revised: 02/18/2016] [Accepted: 02/24/2016] [Indexed: 12/11/2022]
Abstract
AIM This study aimed to determine the association between visceral adipose tissue (VAT), liver fat (LF) content, and other markers of the metabolic syndrome (MetS) and osteoprotegerin (OPG) in dysmetabolic adults. METHODS Subjects from the NUMEVOX cohort were included if they fulfilled at least one MetS criterion. They then underwent a thorough metabolic and cardiovascular evaluation, including arterial stiffness, atherosclerotic plaques, homoeostasis model assessment for insulin resistance (HOMA-IR) indices and OPG. VAT and LF content were measured by magnetic resonance imaging (MRI). Ultrasound examination of arteries and arterial stiffness were recorded, and age- and gender-adjusted paired correlations calculated. RESULTS Body mass index, waist circumference and MRI-derived VAT correlated with OPG, whereas abdominal subcutaneous fat did not. OPG levels were strongly correlated with LF content (r=0.25, P=0.003), liver markers such as alanine aminotransferase (r=0.39, P<0.001) and HOMA-IR index (r=0.39, P<0.0001). Plasma OPG also correlated with arterial stiffness and the number of atherosclerotic sites. CONCLUSION Plasma OPG levels are positively associated with both liver markers and increased LF content, but not with subcutaneous fat in dysmetabolic men. These findings suggest that elevated OPG levels may play a role in the link between fatty liver disease and enhanced cardiovascular risk.
Collapse
Affiliation(s)
- M Monseu
- Department of Internal Medicine, CHU Tours, 2, boulevard Tonnellé, Tours, France.
| | - S Dubois
- Department of Diabetology, CHU, Angers, France.
| | - J Boursier
- Department of Hepatology, CHU, Angers, France.
| | - C Aubé
- Department of Radiology, CHU, Angers, France.
| | - F Gagnadoux
- Department of Pneumology, CHU, Angers, France.
| | - G Lefthériotis
- Department of Vascular Explorations, CHU, Angers, France.
| | - P-H Ducluzeau
- Inserm UMR1069, "Nutrition, Growth and Cancer", CHRU Bretonneau, University of Tours, 37044 Tours, France.
| |
Collapse
|
38
|
Abstract
For 2 × 2 tables, Egon Pearson's N - 1 chi-squared statistic is theoretically more sound than Karl Pearson's chi-squared statistic, and provides more accurate p values. Moreover, Egon Pearson's N - 1 chi-squared statistic is equal to the Mantel-Haenszel chi-squared statistic for a single 2 × 2 table, and as such, is often available in statistical software packages like SPSS, SAS, Stata, or R, which facilitates compliance with Ian Campbell's recommendations.
Collapse
Affiliation(s)
- F M T A Busing
- Psychological Institute, Leiden University, the Netherlands
| | - B Weaver
- Centre for Research on Safe Driving, Lakehead University 955 Oliver Road, Thunder Bay, ON Canada P7B 5E1; Northern Ontario School of Medicine, Human Sciences Division, 955 Oliver Road, Thunder Bay, ON, Canada P7B 5E1
| | - S Dubois
- Centre for Research on Safe Driving, Lakehead University 955 Oliver Road, Thunder Bay, ON Canada P7B 5E1; Northern Ontario School of Medicine, Human Sciences Division, 955 Oliver Road, Thunder Bay, ON, Canada P7B 5E1.,Centre for Applied Health Research, St. Joseph's Care Group, 580 Algoma St. N, Thunder Bay, Ontario, Canada, P7B 5G4
| |
Collapse
|
39
|
Albuquerque T, Isaakidis P, Das M, Saranchuk P, Andries A, Misquita DP, Khan S, Dubois S, Peskett C, Browne M. Infection control in households of drug-resistant tuberculosis patients co-infected with HIV in Mumbai, India. Public Health Action 2015; 4:35-41. [PMID: 26423759 DOI: 10.5588/pha.13.0096] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2013] [Accepted: 01/30/2014] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Mumbai has a population of 21 million, and an increasingly recognised epidemic of drug-resistant tuberculosis (DR-TB). OBJECTIVE To describe TB infection control (IC) measures implemented in households of DR-TB patients co-infected with the human immunodeficiency virus (HIV) under a Médecins Sans Frontières programme. METHODS IC assessments were carried out in patient households between May 2012 and March 2013. A simplified, standardised assessment tool was utilised to assess the risk of TB transmission and guide interventions. Administrative, environmental and personal protective measures were tailored to patient needs. RESULTS IC assessments were carried out in 29 houses. Measures included health education, segregating sleeping areas of patients, improving natural ventilation by opening windows, removing curtains and obstacles to air flow, installing fans and air extractors and providing surgical masks to patients for limited periods. Environmental interventions were carried out in 22 houses. CONCLUSIONS TB IC could be a beneficial component of a comprehensive TB and HIV care programme in households and communities. Although particularly challenging in slum settings, IC measures that are feasible, affordable and acceptable can be implemented in such settings using simplified and standardised tools. Appropriate IC interventions at household level may prevent new cases of DR-TB, especially in households of patients with a lower chance of cure.
Collapse
Affiliation(s)
| | | | - M Das
- Médecins Sans Frontières, Mumbai, India
| | - P Saranchuk
- Southern Africa Medical Unit, Médecins Sans Frontières, Cape Town, South Africa
| | - A Andries
- Médecins Sans Frontières, Mumbai, India
| | - D P Misquita
- School of Health System Studies, Tata Institute of Social Sciences, Mumbai, India
| | - S Khan
- Médecins Sans Frontières, Mumbai, India
| | - S Dubois
- Médecins Sans Frontières, Mumbai, India
| | - C Peskett
- Médecins Sans Frontières, Mumbai, India
| | - M Browne
- Southern Africa Medical Unit, Médecins Sans Frontières, Cape Town, South Africa
| |
Collapse
|
40
|
Camus V, Bouwyn JP, Chamseddine A, Lenain P, Ahtoy P, Stamatoullas A, Lanic H, Lemasle E, Contentin N, Cassuto O, Leprêtre S, Dubois S, Tilly H, Jardin F. Human herpesvirus-6 acute limbic encephalitis after unrelated umbilical cord blood transplantation successfully treated with ganciclovir. Bone Marrow Transplant 2015; 50:1385-7. [PMID: 26146808 DOI: 10.1038/bmt.2015.159] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- V Camus
- Department of Haematology, Centre Henri Becquerel, Rouen, France
| | - J-P Bouwyn
- Department of Neurology, Charles Nicolle University Hospital, Rouen, France
| | - A Chamseddine
- Department of Haematology, Centre Henri Becquerel, Rouen, France
| | - P Lenain
- Department of Haematology, Centre Henri Becquerel, Rouen, France
| | - P Ahtoy
- Department of Neurology, Charles Nicolle University Hospital, Rouen, France
| | - A Stamatoullas
- Department of Haematology, Centre Henri Becquerel, Rouen, France
| | - H Lanic
- Department of Haematology, Centre Henri Becquerel, Rouen, France
| | - E Lemasle
- Department of Haematology, Centre Henri Becquerel, Rouen, France
| | - N Contentin
- Department of Haematology, Centre Henri Becquerel, Rouen, France
| | - O Cassuto
- Department of Haematology, Centre Henri Becquerel, Rouen, France
| | - S Leprêtre
- Department of Haematology, Centre Henri Becquerel, Rouen, France
| | - S Dubois
- Department of Haematology, Centre Henri Becquerel, Rouen, France
| | - H Tilly
- Department of Haematology, Centre Henri Becquerel, Rouen, France
| | - F Jardin
- Department of Haematology, Centre Henri Becquerel, Rouen, France
| |
Collapse
|
41
|
Aguiar A, Ahring K, Almeida MF, Assoun M, Belanger Quintana A, Bigot S, Bihet G, Blom Malmberg K, Burlina A, Bushueva T, Caris A, Chan H, Clark A, Clark S, Cochrane B, Corthouts K, Dalmau J, Dassy M, De Meyer A, Didycz B, Diels M, Dokupil K, Dubois S, Eftring K, Ekengren J, Ellerton C, Evans S, Faria A, Fischer A, Ford S, Freisinger P, Giżewska M, Gokmen-Ozel H, Gribben J, Gunden F, Heddrich-Ellerbrok M, Heiber S, Heidenborg C, Jankowski C, Janssen-Regelink R, Jones I, Jonkers C, Joerg-Streller M, Kaalund-Hansen K, Kiss E, Lammardo AM, Lang K, Lier D, Lilje R, Lowry S, Luyten K, MacDonald A, Meyer U, Moor D, Pal A, Robert M, Robertson L, Rocha JC, Rohde C, Ross K, Saruhan S, Sjöqvist E, Skeath R, Stoelen L, Ter Horst NM, Terry A, Timmer C, Tuncer N, Vande Kerckhove K, van der Ploeg L, van Rijn M, van Spronsen FJ, van Teeffelen-Heithoff A, van Wegberg A, van Wyk K, Vasconcelos C, Vitoria I, Wildgoose J, Webster D, White FJ, Zweers H. Practices in prescribing protein substitutes for PKU in Europe: No uniformity of approach. Mol Genet Metab 2015; 115:17-22. [PMID: 25862610 DOI: 10.1016/j.ymgme.2015.03.006] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/12/2015] [Revised: 03/18/2015] [Accepted: 03/19/2015] [Indexed: 11/16/2022]
Abstract
BACKGROUND There appears little consensus concerning protein requirements in phenylketonuria (PKU). METHODS A questionnaire completed by 63 European and Turkish IMD centres from 18 countries collected data on prescribed total protein intake (natural/intact protein and phenylalanine-free protein substitute [PS]) by age, administration frequency and method, monitoring, and type of protein substitute. Data were analysed by European region using descriptive statistics. RESULTS The amount of total protein (from PS and natural/intact protein) varied according to the European region. Higher median amounts of total protein were prescribed in infants and children in Northern Europe (n=24 centres) (infants <1 year, >2-3g/kg/day; 1-3 years of age, >2-3 g/kg/day; 4-10 years of age, >1.5-2.5 g/kg/day) and Southern Europe (n=10 centres) (infants <1 year, 2.5 g/kg/day, 1-3 years of age, 2 g/kg/day; 4-10 years of age, 1.5-2 g/kg/day), than by Eastern Europe (n=4 centres) (infants <1 year, 2.5 g/kg/day, 1-3 years of age, >2-2.5 g/kg/day; 4-10 years of age, >1.5-2 g/kg/day) and with Western Europe (n=25 centres) giving the least (infants <1 year, >2-2.5 g/kg/day, 1-3 years of age, 1.5-2 g/kg/day; 4-10 years of age, 1-1.5 g/kg/day). Total protein prescription was similar in patients aged >10 years (1-1.5 g/kg/day) and maternal patients (1-1.5 g/kg/day). CONCLUSIONS The amounts of total protein prescribed varied between European countries and appeared to be influenced by geographical region. In PKU, all gave higher than the recommended 2007 WHO/FAO/UNU safe levels of protein intake for the general population.
Collapse
Affiliation(s)
- A Aguiar
- Hospital de Santo Espirito da Ilha Terceira, Portugal
| | - K Ahring
- Kennedy Centre, Department of Clinical Genetics, Rigshospitalet, University of Copenhagen, Glostrup, Denmark
| | - M F Almeida
- Centro de Genética Médica Doutor Jacinto de Magalhães, CHP EPE, Porto, Portugal; Multidisciplinary Unit for Biomedical Research, UMIB-FCT, Porto, Portugal
| | - M Assoun
- Service des Maladies Héréditaires du Métabolisme, Hospital Necker Enfants Malades, Paris, France
| | | | - S Bigot
- Centre Hospitalier Universitaire de Rennes, France
| | - G Bihet
- Centre Hospitalier Chrétien, Centre Pinocchio Liège, Belgium
| | | | - A Burlina
- Division of Inherited Metabolic Diseases, Department of Pediatrics, University Hospital of Padova, Italy
| | - T Bushueva
- Scientific Center of Children's Health, Moscow, Russian Federation
| | - A Caris
- Centre Wallon de Génétique Humaine, Maladies Métaboliques, CHU de Liège Sart-Tilman, Belgium
| | - H Chan
- Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - A Clark
- National Centre for Inherited Metabolic Disorders, Dublin, Ireland
| | - S Clark
- Addenbrooke's Hospital, Cambridge, UK
| | - B Cochrane
- Royal Hospital for Sick Children, Glasgow, Scotland, UK
| | - K Corthouts
- University Hospitals Leuven, Center of Metabolic Diseases, Leuven, Belgium
| | | | - M Dassy
- Cliniques Universitaires St Luc, Brussels, Belgium
| | - A De Meyer
- Center of Metabolic Diseases, University Hospital, Antwerp, Belgium
| | - B Didycz
- University Children's Hospital, Cracow, Poland
| | - M Diels
- University Hospitals Leuven, Center of Metabolic Diseases, ZOL, Genk, Belgium
| | - K Dokupil
- Dr. von Hauner Children's Hospital, Munich, Germany
| | - S Dubois
- Service des Maladies Héréditaires du Métabolisme, Hospital Necker Enfants Malades, Paris, France
| | - K Eftring
- Queen Silvia's Children Hospital, Gothenburg, Sweden
| | - J Ekengren
- Queen Silvia's Children Hospital, Gothenburg, Sweden
| | | | - S Evans
- Birmingham Children's Hospital, Birmingham, UK
| | - A Faria
- Hospital Pediatrico, Centro Hospitalar e Universitário de Coimbra, EPE, Portugal
| | - A Fischer
- Klinikum am Steinenberg, Klinik für Kinder- und Jugendmedizin Reutlingen, Germany
| | - S Ford
- North Bristol NHS Trust Southmead and Frenchay, UK
| | - P Freisinger
- Klinikum am Steinenberg, Klinik für Kinder- und Jugendmedizin Reutlingen, Germany
| | - M Giżewska
- Pomeranian Medical University, Szczecin, Poland
| | - H Gokmen-Ozel
- Haccettepe University Children's Hospital, Ankara, Turkey
| | - J Gribben
- Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - F Gunden
- Uludag University Medical Faculty, Bursa, Turkey
| | | | - S Heiber
- University Hospital, Basel, Switzerland
| | - C Heidenborg
- Karolinska University Hospital, Stockholm, Sweden
| | - C Jankowski
- University Hospitals Bristol NHS Foundation Trust, UK
| | | | - I Jones
- Center of Metabolic Diseases, University Hospital, Antwerp, Belgium
| | - C Jonkers
- Academic Medical Hospital, Amsterdam, Netherlands
| | - M Joerg-Streller
- Medical University of Innsbruck, Clinic for Pediatrics, Inherited Metabolic Disorders, Austria
| | | | - E Kiss
- Semmelweis University, Hungary
| | | | - K Lang
- Ninewells Hospital, Dundee, Scotland, UK
| | - D Lier
- Klinikum am Steinenberg, Klinik für Kinder- und Jugendmedizin Reutlingen, Germany
| | - R Lilje
- Oslo University Hospital Rikshospitalet, Norway
| | - S Lowry
- Sheffield Children's NHS Foundation Trust, Sheffield, UK
| | - K Luyten
- Center of Metabolic Diseases, University Hospital, Antwerp, Belgium
| | - A MacDonald
- Birmingham Children's Hospital, Birmingham, UK.
| | - U Meyer
- Clinic of Paediatric Kidney, Liver and Metabolic Diseases Medical School Hannover, Germany
| | - D Moor
- Kinderspital Zürich, Switzerland
| | - A Pal
- Akademiska University Hospital (Children's Centre), Sweden
| | - M Robert
- Hôpital Universitaire des Enfants, Reine Fabiola, Bruxelles, Belgium
| | | | - J C Rocha
- Centro de Genética Médica Doutor Jacinto de Magalhães, CHP EPE, Porto, Portugal; Faculdade de Ciências da Saúde, Universidade Fernando Pessoa, Porto, Portugal; Center for Health Technology and Services Research (CINTESIS), Portugal
| | - C Rohde
- Hospital for Children and Adolescents, University Hospitals, University of Leipzig, Germany
| | - K Ross
- Royal Aberdeen Children's Hospital, Scotland, UK
| | - S Saruhan
- Haccettepe University Children's Hospital, Ankara, Turkey
| | - E Sjöqvist
- Children's Hospital, University Hospital Skåne, Sweden
| | - R Skeath
- Great Ormond Street Hospital for Children NHS Trust, London, UK
| | - L Stoelen
- Oslo University Hospital Rikshospitalet, Norway
| | | | - A Terry
- Alderhey Children's Hospital, Liverpool, UK
| | | | - N Tuncer
- Dokuz Eylül University Nevvar-Salih İşgören Children Hospital, Turkey
| | - K Vande Kerckhove
- University Hospitals Leuven, Center of Metabolic Diseases, Leuven, Belgium
| | | | - M van Rijn
- University of Groningen, University Medical Center, Groningen, Netherlands
| | - F J van Spronsen
- University of Groningen, University Medical Center, Groningen, Netherlands
| | | | - A van Wegberg
- Radboud University Nijmegen Medical Centre, Netherlands
| | - K van Wyk
- Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - C Vasconcelos
- Centro Hospitalar São João - Unidade de Doenças Metabólicas, Porto, Portugal
| | | | | | - D Webster
- University Hospitals Bristol NHS Foundation Trust, UK
| | - F J White
- Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK
| | - H Zweers
- Radboud University Nijmegen Medical Centre, Netherlands
| |
Collapse
|
42
|
Gauthier AL, Dubois S, Jacquemart AL. USING 3D FLOWERS AS NEW TOOLS TO STUDY BUMBLEBEES BEHAVIOUR. Commun Agric Appl Biol Sci 2015; 80:189-194. [PMID: 26630776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
|
43
|
Campos PHRF, Labussière E, Hernández-García J, Dubois S, Renaudeau D, Noblet J. Effects of ambient temperature on energy and nitrogen utilization in lipopolysaccharide-challenged growing pigs1. J Anim Sci 2014; 92:4909-20. [DOI: 10.2527/jas.2014-8108] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Affiliation(s)
- P. H. R. F. Campos
- INRA, UMR 1348 PEGASE, F-35590 Saint-Gilles, France
- Agrocampus Ouest, UMR1348 PEGASE, F-35000 Rennes, France
| | - E. Labussière
- INRA, UMR 1348 PEGASE, F-35590 Saint-Gilles, France
- Agrocampus Ouest, UMR1348 PEGASE, F-35000 Rennes, France
| | | | - S. Dubois
- INRA, UMR 1348 PEGASE, F-35590 Saint-Gilles, France
- Agrocampus Ouest, UMR1348 PEGASE, F-35000 Rennes, France
| | - D. Renaudeau
- INRA, UMR 1348 PEGASE, F-35590 Saint-Gilles, France
- Agrocampus Ouest, UMR1348 PEGASE, F-35000 Rennes, France
| | - J. Noblet
- INRA, UMR 1348 PEGASE, F-35590 Saint-Gilles, France
- Agrocampus Ouest, UMR1348 PEGASE, F-35000 Rennes, France
| |
Collapse
|
44
|
Tran M, Bédard M, Dubois S, Weaver B, Molloy DW. The influences of psychotic symptoms on the activities of daily living of individuals with Alzheimer disease: a longitudinal analysis. Aging Ment Health 2014; 17:738-47. [PMID: 23425341 DOI: 10.1080/13607863.2013.770446] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
OBJECTIVES Psychotic symptoms associated with Alzheimer Disease (AD) contribute to excess functional dependence. Longitudinal studies have generally examined the association between rates of functional decline and the occurrence of psychotic symptoms from either a single evaluation or from multiple evaluations rather than through changes in frequency and severity of symptoms. Although the presence or absence of psychotic symptoms at initial or follow-up examinations may be associated with changes in functional status, the nature of the relationship between changes in these domains cannot be inferred. We examine the association between changes in the frequency of psychotic symptoms and changes in dependence in activities of daily living (ADL) over a period ranging from 1 to 74 months (median = 17.7). METHOD Data from a cohort of 234 individuals referred to a memory clinic were analyzed using multilevel linear regression. Information on ADL, behavioral and psychological symptoms, depression, and cognition was collected. RESULTS An increase in the frequency of psychotic symptoms had a unique influence on the deterioration of basic ADL, after controlling for demographic variables, changes in cognition, depression, and other behavioral and psychological symptoms (B = -.017, p = .003). However, changes in psychotic symptoms did not significantly contribute to declines in the ability to perform instrumental ADL (B = -.008, p = .439). CONCLUSION Changes in psychotic symptoms may influence basic but not instrumental ADL over time. These findings may have ramifications for studies and treatment plans for individuals with AD who demonstrate psychotic symptoms.
Collapse
Affiliation(s)
- M Tran
- Complex Care Services, St. Joseph's Care Group, Thunder Bay, Ontario, Canada.
| | | | | | | | | |
Collapse
|
45
|
Adam S, Almeida MF, Assoun M, Baruteau J, Bernabei SM, Bigot S, Champion H, Daly A, Dassy M, Dawson S, Dixon M, Dokoupil K, Dubois S, Dunlop C, Evans S, Eyskens F, Faria A, Favre E, Ferguson C, Goncalves C, Gribben J, Heddrich-Ellerbrok M, Jankowski C, Janssen-Regelink R, Jouault C, Laguerre C, Le Verge S, Link R, Lowry S, Luyten K, Macdonald A, Maritz C, McDowell S, Meyer U, Micciche A, Robert M, Robertson LV, Rocha JC, Rohde C, Saruggia I, Sjoqvist E, Stafford J, Terry A, Thom R, Vande Kerckhove K, van Rijn M, van Teeffelen-Heithoff A, Wegberg AV, van Wyk K, Vasconcelos C, Vestergaard H, Webster D, White FJ, Wildgoose J, Zweers H. Dietary management of urea cycle disorders: European practice. Mol Genet Metab 2013; 110:439-45. [PMID: 24113687 DOI: 10.1016/j.ymgme.2013.09.003] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/06/2013] [Revised: 09/04/2013] [Accepted: 09/06/2013] [Indexed: 12/30/2022]
Abstract
BACKGROUND There is no published data comparing dietary management of urea cycle disorders (UCD) in different countries. METHODS Cross-sectional data from 41 European Inherited Metabolic Disorder (IMD) centres (17 UK, 6 France, 5 Germany, 4 Belgium, 4 Portugal, 2 Netherlands, 1 Denmark, 1 Italy, 1 Sweden) was collected by questionnaire describing management of patients with UCD on prescribed protein restricted diets. RESULTS Data for 464 patients: N-acetylglutamate synthase (NAGS) deficiency, n=10; carbamoyl phosphate synthetase (CPS1) deficiency, n=29; ornithine transcarbamoylase (OTC) deficiency, n=214; citrullinaemia, n=108; argininosuccinic aciduria (ASA), n=80; arginase deficiency, n=23 was reported. The majority of patients (70%; n=327) were aged 0-16y and 30% (n=137) >16y. Prescribed median protein intake/kg body weight decreased with age with little variation between disorders. The UK tended to give more total protein than other European countries particularly in infancy. Supplements of essential amino acids (EAA) were prescribed for 38% [n=174] of the patients overall, but were given more commonly in arginase deficiency (74%), CPS (48%) and citrullinaemia (46%). Patients in Germany (64%), Portugal (67%) and Sweden (100%) were the most frequent users of EAA. Only 18% [n=84] of patients were prescribed tube feeds, most commonly for CPS (41%); and 21% [n=97] were prescribed oral energy supplements. CONCLUSIONS Dietary treatment for UCD varies significantly between different conditions, and between and within European IMD centres. Further studies examining the outcome of treatment compared with the type of dietary therapy and nutritional support received are required.
Collapse
Affiliation(s)
- S Adam
- Royal Hospital for Sick Children, Glasgow Royal Infirmary, Glasgow, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Servais A, Arnoux JB, Lamy C, Hummel A, Vittoz N, Katerinis I, Bazzaoui V, Dubois S, Broissand C, Husson MC, Berleur MP, Rabier D, Ottolenghi C, Valayannopoulos V, de Lonlay P. Treatment of acute decompensation of maple syrup urine disease in adult patients with a new parenteral amino-acid mixture. J Inherit Metab Dis 2013; 36:939-44. [PMID: 23250513 DOI: 10.1007/s10545-012-9570-2] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/17/2012] [Revised: 11/21/2012] [Accepted: 11/26/2012] [Indexed: 12/01/2022]
Abstract
BACKGROUND Acute decompensation of maple syrup urine disease (MSUD) is usually treated by enteral feeding with an amino-acid mixture without leucine (Leu), valine or isoleucine. However, its administration is ineffective in cases of gastric intolerance and some adult patients refuse enteral feeding via a nasogastric tube. We developed a new parenteral amino-acid mixture for patients with MSUD. METHODS Seventeen decompensation episodes in four adult patients with MSUD treated with a parenteral amino-acid mixture (group P) were compared to 18 previous episodes in the same patients treated by enteral feeding (group E). RESULTS The mean Leu concentration at presentation was similar in the groups P and E (1196.9 μmol/L and 1212.2 μmol/L, respectively). The mean decrease in the Leu concentration during the first 3 days of hospitalisation was significantly higher in group P than group E (p = 0.0026); there were no side effects. The mean duration of hospitalisation was similar (4 vs. 4.5 days, p = NS). No patient in group P deteriorated whereas one patient in group E required dialysis. CONCLUSION This new parenteral amino-acid mixture is safe and allows efficient Leu concentration decrease during acute MSUD decompensation episodes in adults. Its use avoids the need for nasogastric tube insertion.
Collapse
Affiliation(s)
- A Servais
- Department of Nephrology, Hôpital Necker-Enfants Malades AP-HP, Paris, France,
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Bonnet F, Velayoudom Cephise FL, Gautier A, Dubois S, Massart C, Camara A, Larifla L, Balkau B, Ducluzeau PH. Role of sex steroids, intrahepatic fat and liver enzymes in the association between SHBG and metabolic features. Clin Endocrinol (Oxf) 2013; 79:517-22. [PMID: 23121021 DOI: 10.1111/cen.12089] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/14/2012] [Revised: 09/23/2012] [Accepted: 10/29/2012] [Indexed: 01/01/2023]
Abstract
BACKGROUND SHBG and liver enzymes levels are both associated with the risk of type 2 diabetes. However, the relationship between SHBG with liver enzymes and intrahepatic fat content remain poorly understood. OBJECTIVE To investigate whether SHBG is correlated with glucose and lipids levels and whether this association depends on fatty liver content, liver enzymes or sex hormone concentrations. DESIGN AND PATIENTS We studied 233 dysmetabolic men with measures of plasma SHBG, total testosterone, 17β-oestradiol, glucose, adiponectin, liver enzymes and hepatokines. Intrahepatic liver fat and visceral fat contents were measured by magnetic resonance imaging in 108 of these individuals. RESULTS After adjustment for age, SHBG concentration was inversely correlated with fasting glucose (βstandardized = -0·21, P = 0·0007), HbA1c (βstandardized = -0·27, P < 0·0001), triglycerides (βstandardized = -0·19, P = 0·003) and positively correlated with HDL-Cholesterol (βstandardized = 0·14, P = 0·03). These correlations persisted after adjustment for either total testosterone or 17β-oestradiol levels. SHBG was not related to either fetuin A or FGF 21 concentrations. The inverse association of SHBG with HbA1c and glycaemia was not altered after adjusting for liver markers but was no longer significant after adjustment for hepatic fat content. CONCLUSION The significant association between SHBG and fasting glycaemia, HbA1c and lipid levels in dysmetabolic men was not related to either sex hormones or markers of liver function, but was dependent on intrahepatic fat. This suggests that intrahepatic fat, but not alterations in liver function markers, may be involved in the association between SHBG and glucose and lipid metabolism.
Collapse
Affiliation(s)
- Fabrice Bonnet
- Department of Endocrinology, INSERM UMR 991, University Hospital of Rennes, 2 rue Henri le Guilloux, Rennes Cedex 9, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Madec AM, Cassel R, Dubois S, Ducreux S, Vial G, Chauvin MA, Mesnier A, Chikh K, Bosco D, Rieusset J, Van Coppenolle F, Thivolet C. Losartan, an angiotensin II type 1 receptor blocker, protects human islets from glucotoxicity through the phospholipase C pathway. FASEB J 2013; 27:5122-30. [PMID: 24008754 DOI: 10.1096/fj.13-234104] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
As shown in a large clinical prospective trial, inhibition of the renin-angiotensin system (RAS) can delay the onset of type 2 diabetes in high-risk individuals. We evaluated the beneficial effects of RAS inhibition on β-cell function under glucotoxic conditions. Human islets from 13 donors were cultured in 5.5 mM (controls) or 16.7 mM glucose [high glucose (HG)] for 4 d with or without losartan (5 μM), a selective AT1R blocker, and/or U73122 (2 μM), a selective PLC inhibitor, during the last 2 d. HG induced RAS activation with overexpression of AT1R (P<0.05) and angiotensinogen (P<0.001) mRNAs. HG increased endoplasmic reticulum (ER) stress markers (P<0.001) such as GRP78, sXBP1, and ATF4 mRNAs and Grp78 protein levels (P<0.01). HG also decreased reticular calcium concentration (P<0.0001) and modified protein expressions of ER calcium pumps with reduction of SERCA2b (P<0.01) and increase of IP3R2 (P<0.05). Losartan prevented these deleterious effects and was associated with improved insulin secretion despite HG exposure. AT1R activation triggers the PLC-IP3-calcium pathway. Losartan prevented the increase of PLC β1 and γ1 protein levels induced by HG (P<0.05). U73122 reproduced all the protective effects of losartan. AT1R blockade protects human islets from the deleterious effects of glucose through inhibition of the PLC-IP3-calcium pathway.
Collapse
Affiliation(s)
- Anne-Marie Madec
- 2INSERM U1060/University Lyon 1/Inra 1235, Lyon-Sud Medicine, Faculty, 165 Chemin du Grand Revoyet-BP 12, 69921 Oullins Cedex, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Bertrand P, Maingonnat C, Penther D, Guney S, Ruminy P, Picquenot JM, Mareschal S, Alcantara M, Bouzelfen A, Dubois S, Figeac M, Bastard C, Tilly H, Jardin F. The costimulatory molecule CD70 is regulated by distinct molecular mechanisms and is associated with overall survival in diffuse large B-cell lymphoma. Genes Chromosomes Cancer 2013; 52:764-74. [PMID: 23716461 DOI: 10.1002/gcc.22072] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2013] [Revised: 04/16/2013] [Accepted: 04/17/2013] [Indexed: 12/15/2022] Open
Abstract
In diffuse large B-cell lymphomas (DLBCL), a recurrent deletion of the 19p13 region has recently been described. CD70 and TNFSF9 genes are suspected tumor suppressor genes, but previous studies suggest an oncogenic role for CD70. Therefore, we studied the consequences of variation in CD70 copy number and epigenetic modifications on CD70 expression. Copy-number variation was investigated in 144 de novo DLBCL tissues by comparative genomic hybridization array and quantitative multiplex PCR. Gene expression was assessed by quantitative RT-PCR, and CD70 promoter methylation was determined by pyrosequencing. The 19p13.3.2 region was deleted in 21 (14.6%) cases, which allowed the minimal commonly deleted region of 57 Kb that exclusively includes the CD70 gene to be defined. Homozygous deletions were observed in four (2.7%) cases, and acquired single-nucleotide variations of CD70 were detected in nine (6.3%) cases. CD70 was highly expressed in both germinal centre B-cell-like (GCB) and activated B-cell-like (ABC) DLBCL compared to normal tissue, with distinct molecular mechanisms of mRNA expression regulation. A gene dosage effect was observed in the GCB subtype, whereas promoter methylation was the predominant mechanism of down regulation in the ABC subtype. However, high CD70 expression levels correlated to shorter overall survival in both the GCB (P = 0.0021) and the ABC (P =0.0158) subtypes. In conclusion, CD70 is targeted by recurrent deletions, somatic mutations and promoter hypermethylation, but its high level of expression is related to an unfavorable outcome, indicating that this molecule may constitute a potential therapeutic target in selected DLBCL.
Collapse
Affiliation(s)
- P Bertrand
- Department of Hematology, IRIB, and Centre Henri Becquerel, INSERM, U918 and Normandie University, Rouen, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
|